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Five novel bis(imidazole-imine) gold(III) chelates were synthesized and characterized 
by NMR (1H, 13C, COSY, HSQC, 19F and 31P), FTIR and UV/visible spectroscopy as well as 
high resolution mass spectrometry and in some cases X-ray crystallography. The ligands 
comprised methyl imidazole moieties bridged by a synthetically variable 
di(azomethine) linkage. Five of the ten synthesised ligands were successfully chelated 
to gold(III), these ligands contained propyl, 2,2-dimethyl, 2-hydroxy, 2-methoxy-propyl 
and 2-ethoxy-propyl linkages. The ligands were synthesised by the condensation of two 
equivalents of 4-methyl-5-imidazolecarbaldehyde and the respective diamines. The 
chelate synthesis was achieved with direct metalation using [Bu4N][AuCl4].  
Solid state structures were determined by single crystal X-Ray crystallography for two 
ligands and three gold(III) chelates. The ligands were found to form stable  
hydrogen-bonded networks with the water molecule. The water molecules are found in 
the centre of hydrogen-bonded columns forming hydrogen bonds with the surrounding 
ligand molecules. The anti-configuration of the ligands is required for formation of the 
polymers. The hydrogen-bonded columns are co-linear with the c-axis. The three-
dimensional structure is a result of a cross-linking the columns through additional 
hydrogen bonds. The gold(III) chelates all had a square planar coordination geometry. 
This is the regular geometry of d8 metal ion chelates. Metal ion chelation occurs with 
concomitant deprotonation of the imidazole NH groups; this is in contrast to previously 
reported metal chelates of the related ligands. The deprotonation of the imidazole NH 
yields a dianionic tetradentate N-donor ligand. The average Au-Nimine bond measures 
2.007 Å and the average Au-Nimidazole bond measures 1.993 Å. The coordination 
geometry differed slightly from the ideal square planar geometry with an acute bond 
angle of 80.73˚ (Nimine-Au-Nimidazole). This bond angle is constrained by the bite angle of 
the ligands and resulting 5-membered chelation ring. Au···π and π···π interactions were 
present in the chelates, stabilising various supramolecular structures.  
The chelates were designed to exploit the square planar nature of the gold(III) ion to 
produce metal aromatic metal chelates suitable for DNA intercalation to control the 
proliferation of tumour cells. Both direct DNA binding titrations and competitive DNA 
binding studies did not show any significant affinity towards DNA. The likely reason for 
16 
 
this is that the methyl groups on the imidazole rings, which are required to stabilise the 
metal ion through their inductive effect, prevent the intercalation process. This class of 
compounds therefore needs further development to achieve the final goal of 
chemotherapeutic agent.  
Density Functional Theory (DFT) was used to simulate various properties of the ligands 
and gold(III) chelates. The DFT calculated data was compared to the experimental data 
to determine the efficiency of the chosen basis set and hybrid functional used. DFT was 
also used to deconvolute the experimental data obtained, with particular emphasis on 
the electronic spectra. The level of theory used for ligands was B3LYP/6-311G and for 
the gold(III) chelates PBE1PBE/LanL2DZ. DFT was used to calculate the optimized 
geometry, NMR and electronic spectra. The vibrational frequencies for both ligands and 
chelates showed no negative Eigen values which implies that the optimized geometry is 
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Chapter 1| Introduction 
1.1 Preface  
 
Cancer has been well documented in animals and humans alike throughout history. The earliest 
evidence of cancer comes from ancient Egypt where bone cancer was discovered in mummified 
human remains [1]. Cancer has now been dated to 3000 B.C., yet this disease from biblical times 
still greatly affects the modern population. In fact, it is the second leading cause of death in the 
United States of America. 
Cancer is a group of diseases defined as the uncontrollable and rapid growth of cells in the body. 
There are many forms of cancer such as bladder, breast and prostate cancers. Statistics obtained 
from the National Cancer Institute (NCI, U.S.A.) clearly show a decrease in the number of deaths 
from 1975 until 2010. It can safely be assumed that the decrease in mortality is due to the 
advancement in anti-cancer drugs and chemotherapy. Statistics for the African continent still 
show a high mortality rate. This is due to lack of early detection and limited access to treatment 
[2]. Although statistics based on the U.S.A. population show a decrease in mortality rates, there 
is still a need to continue research into new anti-cancer agents as there are problems associated 
with current treatments. These include unpleasant side-effects and drug resistance in secondary 
tumours [3]. 
It is hypothesised that by including metal ions in the anti-cancer agents it will potentially alter 
their mechanism of action and helps overcome the current issues associated with 
chemotherapy. Cisplatin was the first anti-cancer drug to be used that had a metal centre. 
Although it shows good efficacy, it has several harmful side-effects and tumours can become 
resistant to the drug. These drawbacks have prompted the search for alternative metal-based 
anti-cancer drugs [4].  
The medicinal properties of gold were first discovered in the 1890s when it was found that 
K[Au(CN)2] could kill the bacteria responsible for tuberculosis. It was later found that gold(I) 
thiolate complexes could be used in the treatment of rheumatoid arthritis. Gold(III) complexes 
have until recently not been as intensely studied as those of gold(I) because gold(III) complexes 
are highly reactive, have a high redox potential and poor stability. These properties meant that 
gold(III) would be reduced to gold(I) or metallic gold under physiological conditions. Recently, 
more stable gold(III) complexes have been synthesised using strong sigma-donor ligands to 
stabilise the gold(III) ion. Gold(III) is isoelectronic with platinum(II) i.e. they have a d8 
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configuration which leads to a square-planar geometry and is therefore an ideal scaffold around 
which ligands with DNA recognition elements can be assembled. These factors have allowed the 
applications of gold(III) to expand into medicinal chemistry [4][5]. 
The aim of this project is to synthesise novel bis(imidazole-imine) gold(III) anti-cancer agents 
that will intercalate DNA thus preventing DNA replication and tumour cell growth. The 
complexes have been designed to include a planar aromatic region, a hydrogen bonding region 
and carry a positive charge. They are therefore anticipated to be effective DNA intercalators and 
chemotherapeutic agents. 
1.2 Causes of cancer 
 
Cancer does not have one main cause, but is rather caused by a combination of several factors. 
These can include diet, pollution, alcohol, viral infections, geophysical factors, occupational 
factors, tobacco and genetic factors. These external stimuli lead to a change in the arrangement 
of genes, therefore causing a mutation to occur. Cancer cells arise when critical genes are 
mutated; these mutations lead to the unregulated proliferation of cells forming tumours [6][7]. 
There are many forms of cancer and these grow and divide at different rates. The most common 
form of cancer among men is prostate cancer, the most common form of cancer among women 
is breast cancer and the most common form of preventable cancer in both sexes is lung cancer 
[3]. 
There are many mutations that could lead to cancer, but the most common are defective START 
checkpoint (vida infra), apoptosis malfunction and oncogenes. The cell cycle has three periods: 
cell growth, DNA synthesis and cell division. The length of each period is controlled by chemical 
signals. If the signals malfunction the cell can become cancerous. There are four phases in the 
cell cycle: G1, synthesis, G2 and mitosis. Translation into each phase is regulated by checkpoints. 
Each checkpoint halts the progression through the cycle until important processes such as DNA 
replication are complete or damaged cells are repaired. Two proteins are important to the 
functioning of these checkpoints i.e. cyclin and cyclindependantkinases (CDK). CDK regulates 
the activity of other proteins and cyclin enables CDK to function. One of the most important 
checkpoints is the START checkpoint which is found in mid G1. The START checkpoint 
determines if it is appropriate to move from the G1 phase to the synthesis phase. If the cell is 
driven past the START checkpoint it is committed to another round of DNA replication. In 
tumour cells, checkpoints are deregulated due to defects in genes that control the abundance of 
cyclin and CDK. In normal cells if DNA is damaged the cell pauses before DNA replication to 
25 
 
repair the DNA, but if the START checkpoint is damaged the cell doesn’t pause for damaged DNA 
and the damaged DNA is replicated. These cells are highly prone to becoming cancerous [9].  
Damaged cells can be terminated through apoptosis; controlled cell death. If the apoptosis 
pathway is inhibited abnormal cells can replicate, potentially leading to tumours. Proteolytic 
enzymes called caspases play an import role in apoptosis. These enzymes attack proteins and 
cleave them which results in cells losing their integrity, their chromatin becomes fragmented 
and blebs of cytoplasm form at their surfaces and the cell shrinks. The cell is then engulfed by 
phagocytes. If the apoptosis mechanism is damaged or inactive, a cell that would be terminated 
because of a compromise in genetic integrity will continue to live and replicate and this can lead 
to a tumour [9].  
Researchers have identified two classes of genes which when mutated can contribute to the 
development of cancer. The first class is called oncogenes; these genes have been altered such 
that they are constantly active promoting uncontrolled cell division. The second class is tumour 
suppressor genes, when these falter cell division can no longer be suppressed leading to a 
tumour [6]. 
1.3 Treatment of cancer 
 
There are a range of treatment options available for cancer patients, but the three major forms 
of treatment are radiation, surgery and chemotherapy.  
Radiation therapy is a treatment that uses high energy particles such as X-rays to destroy cancer 
cells. There are three methods for radiation therapy: external, internal and systematic radiation. 
External radiation uses equipment that focuses high energy particles from outside of the 
patient’s body into the tumour. Internal radiation uses a radiation source that is placed near the 
tumour. Since the radiation source is close to the tumour fewer cells are damaged when 
compared to external radiation methods. The radiation source can be placed in a body cavity, 
near the tumour. Systematic radiation uses radioactive drugs to treat the tumour. These drugs 
bind to antibodies that attach to the cancer cells and then radiate the tumour cells [10]. 
Surgery as a cancer treatment is referred to as curative surgery and refers to the surgical 
removal of a tumour. There are several curative surgery types, for example preventive surgery 
which is the removal of benign tissue that is likely to become cancerous and staging surgery to 
determine how much cancer is present and how much has spread [11].  
Chemotherapy involves using a drug to treat a disease; recently it has been associated with the 
drug treatment of cancer. In chemotherapy, drugs are given to a patient in an effort to slow or 
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stop tumour cell growth. The first anti-cancer drug was discovered surreptitiously. Mustard gas 
was first used as a chemical weapon in World War I and was further studied in World War II. In 
World War II when a group of people were accidentally exposed to this chemical weapon, it was 
discovered that their white blood cell count was very low. It was theorized that if it could affect 
the production of white blood cells it could have a similar effect on cancer cells. In the early 
1940’s several patients diagnosed with advanced lymphomas, which is cancer of the white 
blood cells, were treated by intravenous administration of a solution of 1,1-thiobis(2-
chloroethane) (commonly referred to as mustard gas). The treatment proved effective in terms 
of reducing tumour cell growth, but the success was only partial due to the high toxicity of the 
compound [8]. 
Other treatments such as surgery and radiation act only on localised parts of the body targeted, 
for example the lung, whereas chemotherapy can be used to as a local (treat a targeted area) or 
systematic treatment (travels through the body treating cancer cells wherever they are found). 
One of the major advantages of chemotherapy is that it can be used as a treatment for remote 
areas such as the brain where other treatment methods may not be possible. Chemotherapy can 
also be administrated with other treatments, for example: neoadjuvant chemotherapy, where 
chemotherapy is administrated before surgery [13]. 
Chemotherapeutic drugs administered fall into two main categories: cytotoxic and cytostatic 
[14]. 
1.3.1 Cytotoxic chemotherapeutic agents 
 
Cytotoxic drugs work by interfering with DNA replication [14]. Under the cytotoxic category 
there are three main groups:  
Antimetabolites: Molecules that appear to be nucleotides and are therefore integrated into the 
DNA molecule. Once part of the molecule it prevents DNA replication resulting in non-functional 











Figure 1.3.1: Capecitabine (Xeloda), an antimetabolite chemotherapeutic agent. 
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Alkylating agents: Compounds that attach to DNA molecules and distort the shape of the DNA 
molecule preventing replication. The downside to this group is that it also binds to other 









Figure 1.3.2: Cyclophosphamide, an example of an alkylating agent.  
DNA binders: This group of drugs attach to DNA, break the DNA, detach and move to the next 
DNA molecule. Once the drug has bonded to the DNA molecule it blocks transcription or 
prevents enzymes such as topoisomerase from working. They usually work by inhibiting an 
enzyme [13]. An example of this class of chemotherapeutics is 9-aminoacridine which is shown 




Figure 1.3.3: Schematic structure of 9-aminoacridine, an example of a DNA binder. 
These drugs are not cell specific, but target any rapidly dividing cell such as bone marrow and 
hair follicles. This is the reason for the side-effects of this treatment. 
1.3.2 Cytostatic chemotherapeutic agents 
 
Cytostatic drugs target altered biochemical pathways which enable the cancer cells to 
reproduce at a fast rate. Cytostatic drugs are designed to deactivate the altered enzymes and not 
to kill the cell, but instead just to prevent cell reproduction [14]. Shown below in Figure 1.3.4 is 




Figure 1.3.4: Structure of topotecan an example of a cytostatic drug. 
1.4 DNA Intercalating agents 
 
The novel gold(III) chelates proposed in this work are planar with an extended aromatic region. 
They are therefore anticipated to act as DNA intercalators [12][13]. 
DNA is a tightly wound molecule which has a negatively charged phosphate backbone. It 
requires a cationic species for stability. This is provided by histone proteins, but it can also be 
stabilised by metal salts and other small organic molecules [15]. 
Lerman first proposed this DNA binding mode to explain the strong affinity of certain 
heterocyclic dyes for DNA. When DNA is intercalated by a small molecule, it is stiffened, 
stabilised, lengthened and partially unwound. Different intercalators cause the DNA to unwind 
to different degrees. Since the structure of the intercalated DNA has been altered, it leads to 
functional change such as inhibition of replication [16]. 
Drug/DNA interactions can be classified into two major groups: intercalators and groove 
binders. Intercalation involves the insertion of a planar molecule between DNA base pairs, 
which results in a decrease in DNA helical twist and increasing the length of the DNA strand. 
Figure 1.4.1 illustrates the three modes of binding for inorganic compounds with DNA [17]. 
 (a)     (b)    (c) 
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Figure 1.4.1: The three modes of binding for inorganic compounds with DNA. (a) Groove 
binding. (b) Intercalation. (c) Insertion [17]. 
1.4.1 Organic DNA Intercalators 
 
Organic DNA intercalators are typically polyaromatic compounds. These compounds are able to 
intercalate DNA and inhibit nucleic acid synthesis in vivo. Organic anti-cancer drugs can interact 
with DNA in a number of ways such as minor groove binding, major groove binding, 
intercalation between base pairs and threading intercalation. Molecules without any bulky 
functional groups can intercalate without binding to the minor or major groove. Intercalators 
that bind almost entirely with their aromatic region inserted between the guanine-phosphate-
guanine bases are refered to as classic intercalators [18]. An example of a classic intercalator is 
proflavine as shown in Figure 1.4.2. 
NNH2 NH2 
Figure 1.4.2: Structure of Proflavine, a classic intercalator. The fused aromatic ring structure is 
ubiquitous in DNA intercalators. 
1.4.2 Inorganic DNA Intercalators 
 
DNA intercalators are characterized by the presence of an extended electron-deficient planar 
aromatic ring system. When DNA intercalators bind they extend and unwind the negatively 
charged phosphate backbone. The DNA/drug conjugate is stabilised by π-π stacking interactions 
with the planar aromatic region [19]. 
A metallo-intercalator is a metal complex with one or more intercalating ligands. These 
intercalators orientate themselves parallel to base pairs and unwind the DNA strands. The 
aromatic region of the complex intercalates the DNA strand while the metal centre protrudes 
out of the DNA helix. The intercalated ligand anchors the metal centre with respect to the DNA 
strand. These complexes are rigid and have well-defined symmetry. Selective recognition of a 
DNA sequence by a metallo-intercalator can be achieved by matching the functionality of the 
ligands positioned in the major groove with that of the target base pairs [17]. 
Intercalation by the ligands of metal chelates was first illustrated using photophysical methods, 
but by using more extensive techniques like NMR and high resolution crystal structure, the 
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complex binding modes are now well understood. It is found that the intercalating molecule 
enters the DNA double strand via the major groove and then acts as a new base pair. During this 
process no existing base pair is ejected. This intercalation results in the widening of the major 





















Cisplatin (structure shown in Figure 1.5.1) is one of the most widely used chemotherapeutic 
agents. Cisplatin was synthesised in 1945, but its anti-cancer properties were only discovered in 
the mid 1960’s. Since then cisplatin has been extensively used in the fight against cancer. It is 
most effective in the treatment of testicular and ovarian cancer, though it is widely used for 
treating other forms of cancer such as bladder, cervical, head and neck cancers [22]. Although 
effective, cisplatin does have disadvantages. The first disadvantage is severe side-effects, for 
example nausea, vomiting, ototoxicity, neurotoxicity, and nephrotoxicity. These major side 
effects limit the dosage that can be prescribed to patients. A second disadvantage is cisplatin has 
limited aqueous solubility therefore the drug has to be given intravenously as a suspension. 
Finally, the drug is only effective against a few types of cancer. Cancer types such as non-small 
cell lung are resistant to cisplatin while cancers such as ovarian can develop resistance after the 
first treatment [21]. 
Cisplatin is a highly relevant molecule for comparison with gold(III) chemotherapeutics as it is 
one of the metal-based drugs commercially available. The Pt(II) metal centre is also 
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isoelectronic and shares the same coordination geometry with the gold(III) chelates proposed 








Figure 1.5.1: Structure of cisplatin. 
1.5.1 Mechanism of action of cisplatin 
 
Cisplatin works in a two-step process: firstly it enters the cell and binds to non-DNA targets and 
secondly it binds to the DNA of the cell.  
In the non-DNA binding the Pt(II) coordinates to the constituents in the lipid bilayer, which 
contains nitrogen and sulphur atoms, as it passes through the cell wall. In the cytoplasm many 
cellular components have soft nucleocytoplasm sites such as proteins. The most important 
target in the non-DNA aspect of the mechanism is the tripeptide glutathione (GSH).  Cisplatin 
may also alter enzymes, receptors, and proteins via sulphur co-ordination [21]. 
In the DNA binding mechanism the main target for cisplatin is gDNA. The cisplatin attaches to 
the N7 nitrogen atoms of guanine and adenine in the major groove of the double helix because 
this is the most accessible and most reactive site for cisplatin. When bound to the DNA it 
prevents DNA replication from occurring by blocking transcription [21].  
Due to the severe side-effects and acquired resistance to cisplatin, derivatives i.e. carboplatin 
and oxaliplatin (structures shown in Figure 1.5.2) were developed and are available for 
commercial use. Carboplatin was developed in the 1980’s to reduce the side-effects of cisplatin 
while retaining the anticancer properties [20]. In this analogue, the two chlorides are replaced 
with a cyclobutanedicarboxylate ligand. Replacing the chlorides does not eliminate the drugs 
ability to be an anti-cancer agent. Oxaliplatin is a third generation platinum compound and was 
developed to overcome cisplatin resistance. Oxaliplatin shows good antitumour effects in vivo 
and in vitro [22]. The chlorides are replaced by an oxalate ligand and the ammines are replaced 



















(a)                                            (b) 
Figure 1.5.2: Structure of cisplatin derivatives.  (a) Carboplatin and (b) Oxaliplatin. 
Although cisplatin is not an example of a DNA intercalator, as are the gold(III) chelates in this 
work, it is an example of how effective the inclusion of metal ions can be in the synthesis of anti-
cancer agents. 
1.6 DNA topoisomerase I 
 
DNA topoisomerase enzymes manage the topological state of the DNA strand during DNA 
replication and are a common target for chemotherapeutic agents. There are two classes of the 
topoisomerase enzyme i.e. topoisomerase I and topoisomerase II. The first class regulates the 
supercoiled DNA structure and relieves the tension in the DNA strand caused by unwinding and 
winding during DNA replication. It works by causing a single strand break in the DNA which 
allows the torque to spin the broken strand before the relaxed strand is religated. The second 
class passes a region of duplex DNA from the same or a different molecule through a double-
stranded break generated in the DNA helix [23]. The structure of E. coli topoisomerase is 





Figure 1.6.1: Structure of E. coli topoisomerase [32]. 
1.7 DNA topoisomerase I inhibitors 
 
DNA topoisomerase is the target for many anticancer drugs. Topoisomerase inhibitors have two 
categories: catalytic inhibitors and topoisomerase poisons. The topoisomerase poisons are 
cytotoxic and work by stabilising the covalent complexes between the enzyme and DNA. They 
interfere with the religation step and leave the DNA strands unligated. Catalytic inhibitors stop 
the enzyme activity by preventing the enzyme inducing DNA strand breaks.  A well known 
topoisomerase inhibitor is camptothecin [24]. 
Camptothecin is found in the bark of the Chinese camptotheca tree. It was used in China as a 
treatment for many illnesses like psoriasis, leukemia, diseases of the liver and stomach and 
infection of the spleen. In modern medicine, it is used as an anti-cancer agent.  The mode of 
action of camptothecin is that it prevents the topoisomerase I enzyme from producing 
reversible single-strand breaks in DNA during DNA replication. These strand breaks relieve 
torsional strain and allow DNA replication to continue. When camptothecin is present it binds to 
the topoisomerase I enzyme and prevents the topoisomerase I enzyme from functioning and 
thus the enzyme is released from the DNA strand and DNA replication is stopped [25].  
The gold(III) chelates that will be synthesised in this work share many structural features with 
topotecan and other topoisomerase inhibitors such as an aromatic planar region, a hydrogen 
bonding region and have a positive charge. Shown in Figure 1.7.1 is a comparison of the 
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structure of camptothecin and [Au(L4)]+. The red regions are aromatic planar regions and the 





















(a)            (b) 
Figure 1.7.1: Comparison of the structures of (a) Camptothecin, an example of a topoisomerase 
inhibitor and (b) [Au(L4)]+. 
1.8 Gold in medicine 
 
Gold has always been viewed as an extraordinary metal which denotes status, wealth and 
royalty, so naturally ancient civilizations that had access to gold began to explore the medicinal 
properties of this precious metal. Ancient civilizations such as China in 2500 B.C. believed that 
gold could cure or heal people suffering from small pox, ulcers and measles. Japanese traditional 
healers said gold should be placed in food items and in tea to ensure good health. Gold(I) was 
used clinically for the first time in the 1920’s for its in vitro bacteriostatic effect [35]. 
In recent years gold(I) complexes have been used to treat rheumatoid arthritis, which is an 
autoimmune inflammatory disease. Rheumatoid arthritis is characterised by the erosion of 
joints. The first gold compounds used in treatment were aurothioglucose (ATG) and 
aurothiomalate (ATM). The structures of these two drugs are shown below in Figure 1.8.1. 
These drugs were given intramuscularly and were cleared quickly from the plasma, but 
sufficient amounts of the drug were spread throughout the body to allow the compounds to be 
therapeutic. The highest concentration of the drug is found in the kidney which results in 
unwanted nephrotoxicity. ATM and ATG have serious side effects which prompted the synthesis 




(a)         (b) 
Figure 1.8.1: Early gold(I)-based drugs for treatment of rheumatoid arthritis. (a) aurothiomalate 
and (b) aurothioglucose [26]. 
Gold(III) was not seen as a viable option in the fight against cancer due to its high reactivity, 
high redox potential and low stability. It has subsequently been determined that the gold(III) 
ion can be sufficiently stabilised by the use of ligands which donate electron density to the 
electron deficient gold(III) ion. Some of the ligands used for this purpose are polyamines. 
Nitrogen donor ligands, particularly anionic N-donor ligands, are very effective for gold(III) ion 
stabilisation. This breakthrough opened the door for new research. One area the gold(III) ion 
could be used in is anticancer research. Cisplatin has dominated this field and is the benchmark 
for future drugs. Both Pt(II) and gold(III) are d8 metals and both have a square planar geometry. 
So the circumstantial evidence suggests that gold(III) complexes should mimic the anti-cancer 
properties of the popular cisplatin [33]. 
Gold(III) complexes that have been synthesized as anti-cancer drugs contain ligands with 
nitrogen, oxygen and sulphur donor atoms. There are two species of pyridine complexes 
[AuCl3(Hpm)] and [AuCl2(pm)](structures shown in Figure 1.8.2). Both these complexes show 
good cytotoxicity against Tlymphoblastoid and human ovarian cell lines. [Au(phen)Cl2]Cl, 
[Au(terpy)Cl]Cl2, [AuCl(dien)Cl2] and [Au(en)2]Cl3 all showed reasonable stability under 
physiological conditions. The IC50 value for [Au(phen)Cl2]Cl is 7.4 µM and for [AuCl(dien)Cl2] is 
6.0 µM. The Au-azpy bidentate (structure shown in Figure 1.8.2) complex also shows good 
















   













     (c) 
Figure 1.8.2:  Structures of (a) (AuCl3(Hpm)),  (b) AuCl2(pm) and (c) Au-azpy bidentate. 
Gold(III) tetraarylporphyrins, Schiff bases and bis(pyridyl)carboxamidechelates all exhibit  
anti-cancer properties. The IC50 values of the gold(III) porphyrin (general structure shown in 
Figure 1.9.2.) complexes were found to be in the range of 0.11-0.73 µM. It was also noted that 
the gold(III) porphyrins complexes were effective against cisplatin resistant cells , having IC50 
values of 0.17, 0.14 and 0.11 µM against promyelocytic leukemia, nasopharyngeal carcinoma, 
cervical epithelioid carcinoma, hepatocellular carcinoma and oral epidermoid carcinoma. The 
gold(III) Schiff base complexes (structure shown in Figure 1.8.4.) and bis(pyridyl)carboxamide 
(general structure shown in Figure 1.8.5.) compounds displayed IC50 values in the range of 10-
30 µM. These are comparable to cisplatin which has a mean IC50 value of approximately 15 µM 
[26]. 
The gold(III) complexes proposed in this study will share three structural similarities with the 
gold complexes mentioned above. The complexes have a planar aromatic region, a hydrogen 
bonding region and will have a positive charge. They are therefore anticipated to be effective 
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Figure1.8.5: Structure of gold(III) bis(pyridyl)carboxamide. 
Both the gold(III) porphyrins and bis(pyridyl)carboxamide complexes have dianionic, 
tetradentate N-donor ligands. These ligands have been shown to stabilise the gold (III) ion 
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under physiological conditions. This suggests that the ligands proposed in this work which are 
also examples of dianionic tetradentate N-donor ligands will similarly stabilise the gold(III) ion. 
1.9 Schiff bases 
 
The ligands that will be coordinated to gold(III) in this work are examples of Schiff bases. Schiff 
bases are derived from primary amines and carbonyl compounds. These ligands coordinate 
through the azomethine nitrogen atoms. Schiff bases have many applications and are found in 
the food industry, analytical chemistry, catalysis and biological applications [30]. 
A scheme for the general synthesis of a Schiff base is shown in Figure 1.9.1. Schiff base reactions 
are mostly reversible and the use of an acid/base catalyst or heating is employed during the 
reaction. This reaction does not follow a nucleophilic addition, but forms an unstable 
intermediate compound, carbinolamine. Due to the unstable nature of the carbinolamine, it 
eliminates a water molecule. This step leads to the formation of the Schiff base and is the rate 
















Figure 1.9.1: Scheme for a general Schiff base synthesis. 
Schiff bases derived from pyrrole are mainly used in the pharmaceutical field and in 
electroconducting polymers. Imidazole derived Schiff bases are used in a wide range of 
applications in the pharmaceutical field such as anti-fungals, anti-inflammatories, anti-tubular 
activities, anti-depressants, anti-cancer agents and anti-virals. 4-methyl imidazole, one of the 
key compounds in this work, is similarly used in pharmaceuticals as a raw material, but is also 
found in chemical dyes and rubber. Imidazole and 4-methyl imidazole have also been commonly 
39 
 
used as starting material for ligands [26]. These ligands coordinate through the nitrogen atoms 
with a wide variety of transition metals, for example copper(II), manganese(II), nickel(II) and 
zinc(II) [31]. 
 
Figure 1.9.2: Structure of Imidazole derived Schiff bases with a zinc(II) metal centre [31]. 
The methyl imidazole analogues of the ligands proposed for chelation to gold(III) have been 
successfully coordinated to a range of metal ions including zinc(II) and copper(II) [31]. A 
notable feature of the chelates is that the coordination sphere is square planar. This coupled 
with the planarity of the imidazole-imine moiety suggests that these compounds will effectively 
intercalate DNA. The addition of a methyl group at the 4-position of the imidazole would have 
an inductive effect making the nitrogen atoms stronger sigma donors and will likely further 
stabilise the gold(III) ion. 
1.10 Proposed Research  
 
The aim of this project is to synthesise a range of bis(imidazole-imine) ligands. The ligands and 
complexes are varied by the structures of the di(azomethine) linkage. Seven of the ten ligands 
are novel, ligands H2L4, H2L7 and H2L7 have previously been synthesised. Metal chelation will 
require deprotonation of the imidazole NH leading to a dianionic ligand. Coordination of these 
dianionic ligands to the gold(III) ion will yield a monocationic complex. The compounds have 
been designed to intercalate DNA and inhibit the topoisomerase enzyme thus preventing 








The gold(III) complexes have a planar aromatic region, a hydrogen bonding region (in some 
cases) and an overall positive charge. They are therefore anticipated to be effective DNA 
intercalators and chemotherapeutic agents. Both gold(III) porphyrins and gold(III) 
bis(pyridyl)carboxamide complexes have dianionic, tetradentate N-donor ligands. These ligands 
have been shown to stabilize the gold(III) ion under physiological conditions. This suggests that 


































































































Figure 1.10.1: Structures and abbreviated names of the bis(imidazole-imine) Schiff base ligands 
proposed for chelation to gold(III). 
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1.11 Objectives  
 
1. To synthesise a range of bis(imidazole-imine) ligands. 
2. Fully characterize the free ligands by 1H, 13C, IR and UV/visible spectroscopy and mass 
spectrometry.  
3. To synthesise a range of novel bis(imidazole-imine) gold(III) Schiff base complexes. 
4. Fully characterize the gold complexes by 1H, 13C, 19F, 31P, IR and UV/visible spectroscopy 
as well as mass spectrometry.  
5. Study the ligands and metal chelates by single crystal X-ray crystallography. 
6. Computational studies, using DFT (density functional theory), will be performed on free 
ligands and gold(III) complexes. The results of the DFT will be compared to the 
experimental data to determine accuracy as well as to aid in interpretation of the 
experimental data. 
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Chapter 2| Experimental 
2.1 General Methods 
 
All starting materials used in the syntheses were purchased from Sigma-Aldrich (Germany) and 
used as received. Organic solvents were purchased from Merck (South Africa) and were of 
analytical reagent (AR) grade. Harmony gold provided the metallic gold (99.999%) which was 
in the form of gold pellets. Merck silica gel 60 was used for column chromatography. 
2.2 Instrumentation  
 
NMR spectra were recorded with a Bruker Avance III 400 MHz spectrometer equipped with a 
Bruker magnet (9.395 T) using a 5 mm TBIZ probe at the following frequencies: 1H = 400 MHz, 
13C = 100 MHz, 31P = 162 MHz and 19F = 376 MHz. The spectra were recorded at 30 °C. All NMR 
experiments were conducted using Bruker Topspin 2.1, patch level 6. All proton and carbon 
chemical shifts are quoted relative to the solvents used, DMSO-d6: 1H, 2.50 ppm, 13C, 39.52 ppm; 
CDCl3: 1H 7.26 ppm, 13C, 77.16 ppm and CD3OD:1H, 3.31 ppm, 13C, 49.00 ppm. The 2D COSY and 
HSQC data assisted with the assigning of the 1H and 13C NMR spectra for the ligands and metal 
complexes. 
FTIR spectra were recorded using a Bruker Alpha FTIR spectrometer equipped with an ATR 
Platinum Diamond 1 reflectance accessory. The machine acquired the information in 32 scans 
with a spectral resolution of 1.0 cm–1. Electronic spectra were recorded using a Shimadzu UVPC-
1800 double beam UV-vis scanning spectrometer (1.0 cm path length cuvette). Spectra were 
recorded from 800 to 200 nm.  
High resolution mass spectra were recorded with a Waters Acquity-LCT Premier coupled high 
performance liquid chromatograph-mass spectrometer (time-of-flight) using electrospray 
ionization in positive mode. 






2.3 Synthesis of Ligand Precursors   
 






















Figure 2.3.1: Structure and atom numbering scheme of 2,2,12,12-tetramethyl-3,11-dioxo-4,10-
dioxa-5,9-diazatridecan-7-ol. 
Sodium hydrogencarbonate (8.3 g, 99 mmol) was dissolved in a water:acetonitrile mixture  
(190 mL ratio of 1:1). The solution was placed in an ice bath and cooled to 4 ˚C.  
Di-tert-butyldicarbonate (12.8 g, 59 mmol) and 1,3-diamino-2-hydroxypropane (2.5 g,  
27 mmol) were dissolved in the same solvent system (65 mL). This solution was added to the 
cooled solution and stirred in an ice bath for 2 hours. The reaction was warmed to room 
temperature and stirred overnight. The acetonitrile was removed by rotary evaporation. The 
desired amine was then extracted into DCM (3 × 75 mL portions). The organic portions were 
combined and dried over anhydrous sodium carbonate; the DCM was removed by rotary 
evaporation. The crude product was re-crystallized from diethylether/hexane, resulting in 
colourless crystals (7.4 g, 93.5 % yield). The crystals were characterized by 1H and 13C NMR and 
IR spectroscopy. 
1H NMR (400 MHz, CDCl3, 303K)[δ, ppm]: 1.45 (s, 18H, H-1), 3.21 (m, 4H, H-5), 3.75 (m, 2H, H-6 
and H-7), 5.18 (s br, 2H, H-4). 13C NMR (100 MHz, CDCl3, 303k) [δ, ppm]: 28.56 (1), 43.74 (2), 
71.09 (5), 79.86 (6), 157.27 (3). IR (cm-1): 3316m br (OH and NH), 2971 m and 2930 m υ(CH3 
and CH), 1681s υ(C=O). 
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2.3.2 Synthesis of 2-ethoxypropane-1,3-diaminium dichloride 
 
 
Figure 2.3.2: Structure and atom numbering scheme of 2-ethoxypropane-1,3-diaminium 
dichloride. 
The precursor 2,2,12,12-tetramethyl-3,11-dioxo-4,10-dioxa-5,9-diazatridecan-7-ol (2.0 g,  
6.9 mmol) and [Bu4N][HSO4] (0.44 g, 1.3 mmol) were dissolved in toluene (7.5 mL). A 50% 
aqueous solution of NaOH (7.5 mL) and ethyl iodide (1.67 mL, 20.7 mmol) were added to the 
toluene solution. The reaction mixture was then heated to 100 ˚C for 18 hours. The reaction 
mixture was diluted with water (50 mL) and the alkylated compound extracted into 
ethylacetate (75 mL) and washed with 5% brine and dried over anhydrous Na2CO3. The solvent 
was removed by rotary evaporation. The resulting oil was purified by column chromatography 
on silica gel using 1:4 ethylacetate:hexane as the eluent. The alkylated compound was collected 
and the solvent removed by rotary evaporation. The resulting oil was dissolved in HCl in 
dioxane (4 M) and stirred for 4 hours. A white precipitate formed and was separated from the 
HCl solution by centrifugation, washed with THF and diethyl ether and dried over P2O5. The 
product was characterised by 1H NMR spectroscopy. 
1H NMR (400 MHz, D2O, 303 K) [δ, ppm]: 1.21 (t, 3H, H-1), 3.12 (dd, 2H, 3J1=7.13 Hz, 3J2=14.3 Hz, 



















2.3.3 Synthesis of 2-methoxypropane-1,3-diaminium dichloride 
 
 
Figure 2.3.3: Structure and atom numbering scheme of 2-methoxypropane-1,3-diaminium 
dichloride. 
The precursor 2,2,12,12-tetramethyl-3,11-dioxo-4,10-dioxa-5,9-diazatridecan-7-ol (2.0 g,  
6.9 mmol) and [Bu4N][HSO4] (0.44 g, 1.3 mmol)  were dissolved in toluene (7.5 mL). A 50% 
aqueous NaOH solution (7.5 mL) and methyl iodide (1.67 mL, 20.7 mmol) were then added to 
the toluene solution. The reaction mixture was then heated to 100 ˚C for 18 hours. The solution 
was diluted with water (50 mL) and the alkylated compound extracted into ethylacetate  
(75 mL) and washed with 5% brine and dried over anhydrous Na2CO3. The solvent was 
removed by rotary evaporation. The resulting oil was purified by column chromatography on 
silica gel using 1:4 ethylacetate:hexane as the eluent. The alkylated compound was collected and 
the solvent removed by rotary evaporation. The resulting oil was dissolved in HCl in dioxane  
(4 M) and stirred for 4 hours. A white precipitate formed and was separated from the HCl 
solution by centrifugation, washed with THF and diethyl ether and dried over P2O5. The product 
was characterised by 1H NMR spectroscopy. 
1H NMR (400 MHz, D2O, 303 K) [δ, ppm]: 2.77 (s, 3H,H-1), 3.33 (dd, 2H, 3J1=7.13 Hz, 3J2=14.3 Hz, 



















2.4 Synthesis of Ligands  
 
2.4.1 Synthesis of N,N'-bis[(E)-(4-methyl-1H-imidazol-5-yl) 

















Figure 2.4.1: Structure and atom numbering scheme used for H2L1.  
The ligand precursor 4-methyl-1H-imidazole-5-carbaldehyde (0.500 g, 4.54 mmol) was 
dissolved in ethanol (20 mL). To this solution was added 1,3-diaminopropane (0.189 mL, 
2.27 mmol) (ratio of 4-methyl-1H-imidazole-5-carbaldehyde: 1,3-diaminopropane is 2:1). The 
resulting mixture was heated to reflux for 3 hours during which a white precipitate formed. The 
precipitate was isolated by gravity filtration, yielding the final product (0.483 g, 1.86 mmol,  
81.9 % yield). The product was analysed by 1H and 13C NMR, IR and UV/visible spectroscopy as 
well as mass spectrometry.  
1H NMR (400 MHz, CD3OD, 303 K) [δ ppm]: 2.05 (m, 2H, H-7), 2.37 (s, 6H, H-2), 3.56 (s, 4H, H-6), 
7.54(s, 2H, H-1), 8.24(s, 2H, H-5), 12.14 (s, 2H, NH). 13C NMR (100 MHz, DMSO-d6, 303 K), [δ 
ppm]: 10.33 (2), 31.88 (7), 58.15 (6), 128.46 (1), 134.34 (3), 137.50 (4), 150.22 (5). IR (cm-1): 
2931.55 υ(NH), 1645.02 υ(C=N), 1307.49 υ(C-N stretch), 1461.92 υ(C-C aromatic region). UV-
vis (CH3OH) λmax [nm] (ε/ M-1 cm-1): 266 (2.01 × 104). ESI-MS: m/z 281.1491 (M+Na+), 






2.4.2 Synthesis of 2,2-dimethyl-N,N'-bis[(E)-(4-methyl-1H-imidazol-5-


















Figure 2.4.2: Structure and atom numbering scheme used for H2L2. 
The ligand precursor 4-methyl-1H-imidazole-5-carbaldehyde (0.500 g, 4.54 mmol) was 
dissolved in ethanol (20 mL). To this solution was added 2,2-dimethylpropane-1,3-diamine 
(0.273 mL, 2.27 mmol). The resulting mixture was then heated to reflux for 3 hours, yielding a 
yellow solution. The volume of solvent was reduced via a rotary evaporation giving a light 
yellow precipitate. The precipitate was isolated by gravity filtration, yielding the final product 
(0.432 g, 1.51 mmol, 66.5 % yield). The product was analysed by 1H and 13C NMR, IR and 
UV/visible spectroscopy as well as mass spectrometry. 
1H NMR (400 MHz, CD3OD CD3OD, 303 K) [δ ppm]: 0.93 (s, 6H, H-8), 2.32 (s, 6H, H-2), 2.50 (s, 
4H, H-6), 7.56 (s, 2H, H-1), 8.20 (s, 2H, H-5). 13C NMR (100 MHZ, CD3OD, 303 K), [δ ppm]: 10.56 
(2),  
23.55 (8), 36.19 (7), 69.14 (6), 127.73 (1), 133.85 (3), 137.24 (4), 152.27 (5). IR (cm-1):  
2807.19 υ(NH), 1645.85 υ(C=N), 1336.47.49 υ(C-N stretch), 1456.47 υ(C-C aromatic region). 
UV-vis (CH3OH) λmax [nm] (ε/ M-1 cm-1): 267 (1.35 × 105). ESI-MS: m/z 287.1985 (M+), calculated 







2.4.3 Synthesis of N,N'-bis[(E)-1H-imidazol-5-ylmethylidene]propane-  















Figure 2.4.3: Structure and atom numbering scheme used for H2L3.  
The ligand precursor 1H-imidazole-5-carbaldehyde (0.500 g, 5.20 mmol) was dissolved in 
ethanol (20 mL). To this solution was added 1,3 –diaminopropane (0.217 mL, 2.601 mmol). The 
resulting mixture was heated to reflux for 3 hours during which a white precipitate formed. The 
precipitate was isolated by gravity filtration, yielding the final product (0.402 g, 1.75 mmol, 
67.3% yield). The product was analysed by 1H and 13C NMR, IR and UV/visible spectroscopy as 
well as mass spectrometry. 
1H NMR (400 MHz, DMSO-d6, 303 K) [δ ppm]: 1.97 (m, 2H, H-6),  
3.65 (t, 4H, H-5), 7.07 (s, 2H, H-2), 7.19(s, 2H, H-1), 8.19(s, 2H, H-4), 12.57 (s, 2H, NH). 13C NMR 
(100MHz, DMSO-d6, 303 K), [δ ppm]: 32.19 (6), 58.29 (5), 119.59 (2), 130.08 (1), 145.04 (3), 
152.76 (4). IR (cm-1): 2831.54 υ(NH) 1648.24, υ(C=N), 1387.39 υ(C-N stretch), 1447.73 υ(C-C 
aromatic region). UV-vis (CH3OH) λmax [nm] (ε/ M-1 cm-1): 273.5 (9.00 × 104). ESI-MS: m/z 







2.4.4 Synthesis of N,N'-bis[(E)-1H-imidazol-5-ylmethylidene]propane-



















Figure 2.4.4: Structure and atom numbering scheme used for H2L4.  
The ligand precursor 4-methyl-1H-imidazole-5-carbaldehyde (0.500 g, 4.54 mmol) was 
dissolved in ethanol (20 mL). To this solution was added 1,3-diamino-2-propanol (0.204 g,  
2.27 mmol). The resulting mixture was then heated to reflux for 3 hours during which a pale 
pink precipitate formed. The precipitate was isolated by gravity filtration and was washed with 
ethanol, yielding the final product (0.412g, 1.50 mmol, 66.1% yield). The product was analysed 
by 1H and 13C NMR, IR and UV/visible spectroscopy as well as mass spectrometry. 
1H NMR (400 MHz, DMSO-d6, 303 K) [δ, ppm]: 2.31 (s, 6H, H-2), 2.45 (s, 1H, H-8),  
3.48  (dd, 2H, 6J1=6.4 Hz, 6J2=11.2 Hz, H-6), 3.68  (dd, 2H, 6J1=6.1 Hz, 6J2=7.2 Hz, H-6),   
3.91 (m, 1H, H-7), 7.13(s, 2H, H-1), 8.19 (s, 2H, H-5), 12.11 (s, 2H, NH). 13C NMR (100 MHZ, 
DMSO-d6, 303 K) [δ ppm]: 10.29 (2), 56.52 (7), 65.79 (6), 126.00 (1), 137.06 (3), 141.42 (4), 
151.79 (5). IR (cm-1): 2848.34 υ(NH), 1648.24 υ(C=N), 1387.39 υ(C-N stretch), 1447.73 υ(C-C 
aromatic region). UV-vis (CH3OH) λmax [nm] (ε/ M-1 cm-1): 267.5 (1.37 × 105).  






2.4.5 Synthesis of N,N'-bis[(1E)-(4-methyl-1H-imidazol-5-




















Figure 2.4.5: Structure and atom numbering scheme used for H2L5.  
The ligand precursor 4-methyl-1H-imidazole-5-carbaldehyde (0.500 g, 4.54 mmol) was 
dissolved in ethanol (20 mL). To this solution was added 1,4-diaminobutane (0.228 mL,  
2.27 mmol). The resulting mixture was then heated to reflux for 3 hours during which a pale 
yellow precipitate formed. The precipitate was isolated by gravity filtration, yielding the final 
product (0.372 g, 1.37 mmol, 60.4% yield). The product was analysed by 1H and 13C NMR, IR and 
UV/visible spectroscopy as well as mass spectrometry. 
1H NMR (400 MHz, CD3OD/ CDCl3, 303 K) [δ ppm]:1.62 (m, 4H, H-7), 2.26 (s, 6H, H-2),  
3.51 (t, 4H, H-6), 7.52 (s, 2H, H-1), 8.27 (s, 2H, H-5). 13C NMR (100 MHz, CD3OD/ CDCl3,  
303 K), [δ ppm]: 11.38 (2), 28.59 (7), 60.37 (6), 124.96 (1), 136.86 (3), 142.81 (4), 150.69 (5). 
 IR (cm-1): 2856.69 υ(NH), 1645.38 υ(C=N), 1356.92 υ(C-N stretch), 1443.84 υ(C-C aromatic 
region); UV-vis (CH3OH) λmax [nm] (ε/ M-1 cm-1): 265 (3.0 × 104).  


























Figure 2.4.6: Structure and atom numbering scheme used for H2L6.  
The ligand precursor 4-methyl-1H-imidazole-5-carbaldehyde (0.500 g, 4.54 mmol) was 
dissolved in ethanol (20 mL). To this solution was added (1S,2S)-(+)-1,2-diaminocyclohexane 
(0.273 mL, 2.27 mmol). The resulting mixture was then heated to reflux for 3 hours after which 
a clear brown solution was obtained. The volume of solvent was reduced via rotary evaporation 
and a brown oil formed from which a brown precipitate formed on standing overnight  
(0.536 g, 1.80 mmol , 79.3% yield). The product was analysed by 1H and 13C NMR, IR and 
UV/visible spectroscopy as well as mass spectrometry. 
1H NMR (400 MHz, DMSO-d6, 303 K) [δ ppm]: 1.40 (m, 4H, H-8), 1.77 (m, 4H, H-7),  
2.29 (s, 6H, H-2), 3.21 (m, 2H, H-6), 7.44 (s, 2H, H-1), 8.06 (s, 2H, H-5) , 12.00 (s, 2H, NH).  
13C NMR (100 MHz, DMSO-d6, 303 K) [δ ppm]: 11.88 (2), 24.65 (8), 33.57 (7), 74.20 (6),  
125.96 (1), 136.67 (3), 141.62 (4), 150.09 (5). IR (cm-1): 2847.77 υ(NH), 1634.61 υ(C=N), 
1362.30 υ(C-N stretch), 1443.57 υ(C-C aromatic region). UV-vis (CH3OH) λmax [nm] (ε/ M-1 cm-1): 



























Figure 2.4.7: Structure and atom numbering scheme used for H2L7.  
The ligand precursor 4-methyl-1H-imidazole-5-carbaldehyde (0.500 g, 4.54 mmol) was 
dissolved in ethanol (20 mL). To this solution was added (1R,2R)-(-)-1,2-diaminocyclohexane 
(0.273 mL, 2.27 mmol). The resulting mixture was then heated to reflux for 3 hours, after which 
a clear brown solution was obtained.  The volume of solvent was reduced via rotary evaporation 
leaving a brown oil from which a brown precipitate formed on standing (0.554 g,  
1.86 mmol, 81.9% yield). The product was analysed by 1H and 13C NMR, IR and UV/visible 
spectroscopy as well as mass spectrometry. 
1H NMR (400 MHz, DMSO-d6, 303 K) [δ ppm]: 1.40 (m, 4H, H-8), 1.76 (m, 4H, H-7), 2.13 (s, 6H, 
H-2), 3.20 (m, 2H, H-6), 7.45 (s, 2H, H-1), 8.07 (s, 2H, H-5) , 12.02 (s, 2H, NH). 13C NMR  
(100 MHz, DMSO-d6, 303 K) [δ ppm]: 11.6(2), 24.62(8), 33.36 (7), 58.20 (6), 130.18 (1), 136.14 
(3), 138.02 (4), 152.04 (5). IR (cm-1): 2853.12 υ(NH), 1645.38 υ(C=N), 1356.91 υ(C-N stretch), 
1443.84 υ(C-C aromatic region). UV-vis (CH3OH) λmax [nm] (ε/ M-1 cm-1): 268 (2.4 × 104).   





2.4.8 Synthesis of N,N'-bis[(1E)-(4-methyl-1H-imidazol-5-

















Figure 2.4.8: Structure and atom numbering scheme used for H2L8.  
The ligand precursor 4-methyl-1H-imidazole-5-carbaldehyde (0.500 g, 4.54 mmol) was 
dissolved in ethanol (20 mL). To this solution was added 1,2-diaminoethane (0.152 mL,  
2.27 mmol). The resulting mixture was then heated to reflux for 3 hours during which a pale 
yellow precipitate formed. The precipitate was isolated by gravity filtration, yielding the final 
product (0.421 g, 1.72 mmol, 75.8% yield). The product was analysed by 1H and 13C NMR, IR and 
UV/visible spectroscopy as well as mass spectrometry. 
1H NMR (400 MHz, CD3OD/ CDCl3, 303 K) [δ ppm]: 2.26 (s, 6H, H-2), 3.82 (s, 4H, H-6),  
7.52 (s, 2H, H-1), 8.20 (s, 2H, H-5), 12.09 (s, 1H, NH). 13C NMR (100 MHZ, CD3OD/ CDCl3, 303 K), 
[δ ppm]: 15.32 (2), 60.06 (6), 129.51 (1), 140.53 (3), 145.56 (4), 156.63 (5). IR (cm-1):  
2841.43 υ(NH), 1634.63 υ(C=N), 1356.92 υ(C-N stretch), 1443.94 υ(C-C aromatic region). UV-
vis (CH3OH) λmax [nm] (ε/ M-1 cm-1): 265 (2.3 × 104). ESI-MS: m/z 267.1339 (M+Na+), calculated 








2.4.9 Synthesis of 2-ethoxy-N,N'-bis[(1E)-(4-methyl-1H-imidazol-5-





















Figure 2.4.9: Structure and atom numbering scheme used for H2L9. 
The ligand precursor 2-ethoxy-1,3-diaminopropane dihydrochloride (0.500 g, 2.62 mmol) was 
placed in a pestle and mortar with sodium carbonate (0.555 g, 5.23 mmol ) and the mixture 
ground together until a white paste was formed; a mixture of 2-ethoxy-1,3-diaminopropane and 
sodium chloride. 1H-imidazole-5-carbaldehyde (0.576 g, 5.23 mmol) was then added to the 
pestle and mortar together with 5 drops of piperidine. The mixture was ground together 
resulting in a pale brown solid. The solid was washed with distilled water and air dried (0.602 g, 
1.99 mmol, 76.0% yield). The product was analysed by 1H and 13C NMR, IR and UV/visible 
spectroscopy as well as mass spectrometry. 
1H NMR (400 MHz, DMSO-d6, 303 K) [δ ppm]: 1.02 (s, 3H, H-9), 2.08 (s, 4H, H-6),  
2.31 (m, 6H, H-2), 3.54 (m, 2H, H-8), 3.70(m, 1H, H-7), 7.52 (s, 2H, H-1), 8.20 (s, 2H, H-5) , 12.18 
(s, 1H, NH). 13C NMR (100 MHz, CD3OD, 303 K), [δ ppm]: 10.00 (9), 14.39 (2), 62.29 (8),  
65.17 (7), 78.79 (6), 128.07 (1), 137.38 (3), 142.32 (4), 153.76 (5). IR (cm-1): 2857.24 υ(NH), 
1646.22 υ(C=N), 1342.15 υ(C-N stretch), 1433.33 υ(C-C aromatic region). UV-vis (CH3OH) λmax 
[nm] (ε/ M-1 cm-1): 266(1.1×104). ESI-MS: m/z 325.1758 (M+Na+),  
calculated m/z: 325.17473 (M+Na+). 
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Figure 2.4.10: Structure and atom numbering scheme used for H2L10. 
The ligand precursor 2-methoxy-1,3-diaminopropane dihydrochloride (0.500 g, 2.83 mmol) was 
ground together with sodium carbonate (0.453 g, 5.54 mmol) in a pestle and mortar until a 
white paste was formed; a mixture of 2-ethoxy-1,3-diaminopropane and sodium chloride.  
1H-imidazole-5-carbaldehyde was then added to the pestle and mortar together with 5 drops of 
piperidine and the mixture ground further resulting in a pale brown solid. The solid was then 
washed with distilled water and air dried (0.643 g, 2.23 mmol, 79.0% yield). The product was 
analysed by 1H and 13C NMR, IR and UV/visible spectroscopy as well as mass spectrometry. 
1H NMR (400 MHz, CD3OD, 303 K) [δ ppm]: 2.39 (s, 6H, H-2), 3.33 (s, 3H, H-8), 3.73 (d, 4H, H-6), 
3.83 (m, 1H, H-7), 7.66 (s, 2H, H-1), 8.30 (s, 2H, H-5). 13C NMR (100 MHz, CD3OD, 303 K),  
[δ ppm]: 10.07 (2), 56.68 (8), 61.79 (7), 80.67 (6), 127.87 (1), 136.00 (3), 142.43 (4), 154.03 (5). 
IR (cm-1): 2857.36 υ(NH), 1644.80 υ(C=N), 1352.16 υ(C-N stretch), 1440.11 υ(C-C aromatic 
region). UV-vis (CH3OH) λmax [nm] (ε/ M-1 cm-1): 266 (1. 2 × 104).  





2.5 Synthesis of Complexes 
 
2.5.1 Synthesis of 5,5'-{propane-1,3-diylbis [nitrilo(E) methylylidene]} 























Figure 2.5.1: Structure and atom numbering scheme used for [Au(L1)](PF6). 
[Bu4N][AuCl4] (0.100 g, 0.172 mmol) was dissolved in DCM (10 mL) in a round bottom flask 
with two molar equivalents of [Bu4N][PF6] (0.133 g, 0.344 mmol). The ligand (0.0889 g,  
0.344 mmol) was dissolved in ethanol (10 mL) and added to the solution of [Bu4N][AuCl4] and 
[Bu4N][PF6]. The resulting mixture was heated to reflux for 3 hours during which a mustard-
coloured precipitated formed. The precipitate was isolated by gravity filtration and was washed 
with ethanol, yielding the final product (0.0677 g, 0.113 mmol, 65.7% yield). The product was 
analysed by 1H and 13C NMR, IR and UV/visible spectroscopy as well as mass spectrometry. 
1H NMR (400 MHz, DMSO-d6) [δ ppm]: 1.92 (m, 2H, H-7), 2.54 (s, 6H, H-2), 3.77 (t, 4H, H-6), 8.45 
(s, 2H, H-1), 8.88 (s, 2H, H-5). 13C NMR (100 MHz, DMSO-d6, 303 K) [δ ppm]: 25.62 (2), 36.65 
(7), 51.99 (6), 134.59 (1), 147.69 (3), 152.65 (4), 162.23 (5); 31P NMR (162 MHz, DMSO-d6, 303 
K)[δ ppm]: -144.18 (PF6); 19F (376 MHz, DMSO-d6, 298K)[δ ppm]: -71.11, -69.23(PF6). IR (cm-1): 
1597.51 cm-1 υ(C=N), 1297.39cm-1 υ(C-N stretch), 1448.08 cm-1 υ(C-C aromatic region). UV-vis 
(DMSO) λmax [nm] (ε/ M-1 cm-1): 270 (3.6 × 104), 339 (1.5 × 104). ESI-MS: m/z 453.1110 (M+), 
calculated m/z: 453.1107 (M+). 
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Figure 2.5.2: Structure and atom numbering scheme used for [Au(L2)](PF6). 
[Bu4N][AuCl4] (0.100g, 0.172 mmol) was dissolved in DCM (10 mL) in a round bottom flask with 
two molar equivalents of [Bu4N][PF6] (0.133 g, 0.344 mmol). The ligand (0.0985 g,  
0.344 mmol) was dissolved in ethanol (10 mL) and added to the solution of [Bu4N][AuCl4] and 
[Bu4N][PF6]. The resulting solution was heated to reflux for 3 hours during which a yellow-
orange precipitated formed. The precipitate was isolated by gravity filtration and washed with 
ethanol, yielding the final product (0.0761 g, 0.122 mmol, 70.9% yield). The product was 
analysed by 1H and 13C NMR, IR and UV/visible spectroscopy as well as mass spectrometry. 
1H NMR (400 MHz, DMSO-d6, 303 K) [δ ppm]: 1.08 (s, 6H, H-8), 2.53 (s, 6H, H-2),  
3.47 (s, 4H, H-6), 8.46 (s, 2H, H-1), 8.81 (s, 2H, H-5). 13C NMR (100 MHz, DMSO-d6, 303 K), [δ 
ppm]: 13.93 (2), 14.68 (8), 23.30 (7), 61.62 (6), 134.66 (1), 147.97 (3), 153.20 (4), 162.98 (5). 
31P NMR (162 MHz, DMSO-d6, 303 K)[δ ppm]: -144.18 (PF6). 19F (376 MHz, DMSO-d6, 298K) 
[δ ppm]: -71.11,-69.23 (PF6). IR (cm-1): 1597.30 cm-1 υ(C=N), 1278.13 cm-1 υ(C-N stretch),  
1445.25 cm-1 υ(C-C aromatic region). UV-vis (DMSO) λmax [nm] (ε/ M-1 cm-1): 261 (1.9 × 104), 


























Figure 2.5.3: Structure and atom numbering scheme used for [Au(L3)](PF6). 
[Bu4N][AuCl4] (0.100g, 0.172 mmol) was dissolved in DCM (10 mL) in a round bottom flask with 
two molar equivalents of [Bu4N][PF6] (0.133 g, 0.344 mmol). The ligand (0.0792 g,  
0.344 mmol) was dissolved in ethanol (10 mL) and added to the solution of [Bu4N][AuCl4] and 
[Bu4N][PF6]. The resulting solution was heated to reflux for 3 hours during which no complex 












2.5.4 Synthesis of 5,5'-{(2-hydroxypropane-1,3-
diyl)bis[nitrilo(E)methylylidene]}bis(4-methylimidazol-1-ide) 























Figure 2.5.4: Structure and atom numbering scheme used for [Au(L4)](Cl). 
[Bu4N][AuCl4] (0.100g, 0.172 mmol) was dissolved in DCM (10 mL) in a round bottom flask with 
two molar equivalents of [Bu4N][PF6] (0.133 g, 0.344 mmol). The ligand (0.0944 g,  
0.344 mmol) was dissolved in ethanol (10 mL) and added to the solution of [Bu4N][AuCl4] and 
[Bu4N][PF6]. The resulting solution was heated to reflux for 3 hours during which a dark yellow 
precipitate formed. The precipitate was isolated by gravity filtration and washed with ethanol, 
yielding the final product (0.0517 g, 0.102 mmol, 59.3% yield). The product was analysed by 1H 
and 13C NMR, IR and UV/visible spectroscopy as well as mass spectrometry. 
1H NMR (400 MHz, DMSO-d6, 303 K) [δ ppm]: 2.53 (s, 6H, H-2), 3.74  (dd, 2H, 6J1=5.8 Hz, 6J2=8.8 
Hz, H-6) , 3.85 (dd, 2H, H-6), 4.48 (m, 1H, H-7), 5.79 (d, 1H, H-8), 8.44 (s, 2H, H-1),  
8.94 (s, 2H, H-5). 13C NMR (100 MHz, DMSO-d6, 303 K), [δ ppm]: 14.60 (2), 56.14 (7), 68.60 (6), 
134.75 (1), 148.01 (3), 152.97 (4), 163.51 (5). IR (cm-1): 1598.44 cm-1 υ(C=N),  
1282.79 cm-1 υ(C-N stretch), 1440.11 cm-1 υ(C-C aromatic region). UV-vis (DMSO) λmax [nm] (ε/ 
M-1 cm-1): 265 (2.6 × 104), 339(2.1 × 104). ESI-MS: m/z 469.1050 (M+), 






2.5.5 Attempted synthesis of 5,5'-{butane-1,4-
diylbis[nitrilo(E)methylylidene]}bis(4-methylimidazol-1-ide) 
























Figure 2.5.5: Structure and atom numbering scheme used for [Au (L5)](PF6). 
[Bu4N][AuCl4] (0.100g, 0.172 mmol) was dissolved in DCM (10 mL) in a round bottom flask with 
two molar equivalents of [Bu4N][PF6] (0.133 g, 0.344 mmol). The ligand (0.0937 g,  
0.344 mmol) was dissolved in ethanol (10 mL) and added to the solution of [Bu4N][AuCl4] and 
[Bu4N][PF6]. The resulting solution was heated to reflux for 3 hours during which no complex 







































Figure 2.5.6: Structure and atom numbering scheme used for [Au(L6)](PF6). 
[Bu4N][AuCl4] (0.100g, 0.172 mmol) was dissolved in DCM (10 mL) in a round bottom flask with 
two molar equivalents of [Bu4N][PF6] (0.133 g, 0.344 mmol). The ligand (0.103 g,  
0.344 mmol) was dissolved in ethanol (10 mL) and added to the solution of [Bu4N][AuCl4] and 
[Bu4N][PF6]. The resulting solution was heated to reflux for 3 hours during which no complex 












2.5.7  Attempted  synthesis of 5,5'-{(1R,2R)-cyclohexane-1,2-
diylbis[nitrilo(E)methylylidene]}bis(4-methylimidazol-1-ide) 

























Figure 2.5.7: Structure and atom numbering scheme used for [Au(L7)](PF6). 
[Bu4N][AuCl4] (0.100g, 0.172 mmol) was dissolved in DCM (10 mL) in a round bottom flask with 
two molar equivalents of [Bu4N][PF6] (0.133 g, 0.344 mmol). The ligand (0.103 g,  
0.344 mmol) was dissolved in ethanol (10 mL) and added to the solution of [Bu4N][AuCl4] and 
[Bu4N][PF6]. The resulting solution was heated to reflux for 3 hours during which no complex 











2.5.8  Attempted synthesis of 5,5'-{(2,2-dimethylethane-1,3-
diyl)bis[nitrilo(E) methylylidene]}bis(4-methylimidazol-1-























Figure 2.5.8: Structure and atom numbering scheme used for [Au(L8)](PF6). 
[Bu4N][AuCl4] (0.100g, 0.172 mmol) was dissolved in DCM (10 mL) in a round bottom flask with 
two molar equivalents of [Bu4N][PF6] (0.133 g, 0.344 mmol). The ligand (0.0840 g,  
0.344 mmol) was dissolved in ethanol (10 mL) and added to the solution of [Bu4N][AuCl4] and 
[Bu4N][PF6]. The resulting solution was heated to reflux for 3 hours during which no complex 











2.5.9  Synthesis of 5,5'-{(2-ethoxypropane-1,3-
diyl)bis[nitrilo(E)methylylidene]}bis(4-methylimidazol-1-ide) 

























Figure 2.5.9: Structure and atom numbering scheme used for [Au(L9)](Cl). 
[Bu4N][AuCl4] (0.100g, 0.172 mmol) was dissolved in DCM (10 mL) in a round bottom flask with 
two molar equivalents of [Bu4N][PF6] (0.133 g, 0.344 mmol). The ligand (0.104 g,  
0.344 mmol) was dissolved in ethanol (10 mL) and the ligand solution added to the 
[Bu4N][AuCl4] and [Bu4N][PF6] mixture. The resulting solution was heated to reflux for 3 hours 
during which the solution turned yellow-orange. The solvent volume was reduced by rotary 
evaporation yielding an orange precipitate. The precipitate was isolated by gravity filtration and 
washed with THF (0.0125 g, 0.023 mmol, 13.4%). The product was analysed by 1H and 13C NMR, 
IR and UV/visible spectroscopy as well as mass spectrometry. 
1H NMR (400 MHz, DMSO-d6 , 303 K) [δ ppm]: 1.10 (t, 3H, H-9), 2.54 (s, 6H, H-2),  
3.57 (m, 2H, H-8), 3.95 (d, 4H, H-6), 4.37 (m, 1H, H-7), 8.44 (s, 2H, H-1), 8.95 (s, 2H, H-5). 13C 
NMR (100 MHz, DMSO-d6, 303 K), [δ ppm]: 14.60 (2), 15.60 (9), 53.27 (8), 63.97 (7), 75.16 (6), 
134.59 (1), 148.01 (3), 152.97 (4), 163.19 (5). IR (cm-1): 1597.49 cm-1 υ(C=N), 1295.02 cm-1 υ(C-
N stretch), 1350.17 cm-1 υ(C-C aromatic region). UV-vis (DMSO) λmax [nm] (ε/ M-1 cm-1):  




2.5.10  Synthesis 5,5'-{(2-methoxypropane-1,3-
diyl)bis[nitrilo(E)methylylidene]}bis(4-methylimidazol-1-ide) 


























Figure 2.5.10: Structure and atom numbering scheme used for [Au(L10)](PF6). 
[Bu4N][AuCl4] (0.100g, 0.172 mmol) was dissolved in DCM (10 mL) in a round bottom flask with 
two molar equivalents of [Bu4N][PF6] (0.133 g, 0.344 mmol). The ligand (0.0991 g,  
0.344 mmol) was dissolved in ethanol (10 mL) and the ligand solution added to the 
[Bu4N][AuCl4] and [Bu4N][PF6] mixture. The resulting solution was heated to reflux for 3 hours 
during which a yellow-orange precipitated formed. The precipitate was isolated by gravity 
filtration and washed with ethanol, yielding the final product (0.759 g, 0.121 mmol, 70.3% 
yield). The product was analysed by 1H and 13C NMR, IR and UV/visible spectroscopy as well as 
mass spectrometry. 
1H NMR (400 MHz, DMSO-d6, 303 K) [δ ppm]: 2.54 (s, 6H, H-2), 3.36 (s, 3H, H-8),  
4.03 (d, 4H, H-6), 4.26 (m, 1H, H-7), 8.45 (s, 2H, H-1), 8.93 (s, 2H, H-5). 13C NMR (100 MHz, 
DMSO-d6, 298 K), [δ ppm]: 14.71 (2), 52.69 (6), 56.71(8), 76.84 (7), 134.41 (1), 148.06 (3), 
153.14 (4), 163.46 (5). 31P NMR (162 MHz, DMSO-d6, 303 K) [δ ppm]: -144.18 (PF6). 19F (376 
MHz, DMSO-d6, 303 K)[δ ppm]:- 71.11,-69.23 (PF6). IR (cm-1): 1598.02 cm-1 υ(C=N), 1291.14 cm-
1 υ(C-N stretch), 1410.96 cm-1 υ(C-C aromatic region). UV-vis (DMSO) λmax [nm] (ε/ M-1 cm-1):  
267 (2.54 × 104), 340 (5.1  × 103). ESI-MS: m/z 483.1226 (M+), calculated m/z: 483.1212 (M+). 
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Chapter 3| Synthesis 
3.1 Introduction  
 
Schiff Base ligands were chosen to help stabilise the gold(III) ion in this research. These Schiff 
base ligands were synthesized via a condensation reaction between a carbonyl and primary 
amine. This reaction was first discovered by Hugo Schiff in 1864 [1]. The general mechanism for 
the synthesis of a Schiff base is shown in Scheme 3.1. The synthesis actually occurs in three 
steps: firstly the lone pair of electrons on the nitrogen atom attacks the carbonyl carbon forming 
a bond between the nitrogen and carbon. The positively charged nitrogen loses one hydrogen, 
which bonds to the negatively charged oxygen forming an OH group boned to the “carbonyl” 
carbon. Finally, the OH group and the remaining hydrogen on the nitrogen leave as water and 
the Schiff base is formed. The lone pair of electrons on the nitrogen atom of the imine bond 





































Scheme 3.1: General mechanism for a Schiff base reaction. [2] 
These Schiff base ligands have been successfully coordinated to gold(III) as they are effective 
sigma-donor groups able to stabilise the metal in its high oxidation state. The aim of my project 
was to synthesise a range of bis(imidazole-imine) ligands and coordinate them to gold(III) to 
form novel metal-based chemotherapeutic agents. This high oxidation state of gold(III) is 
potentially unstable in the presence of biological reducing agents such as glutathione thus 
strong sigma-donor ligands are required for stability. The ligands will be dianionic when the 
imidazole NH is deprotonated. Coordination of these dianionic ligands to the gold(III) ion will 
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yield a monocationic complex. The addition of a methyl group at the 4- position on the imidazole 
ring would have an inductive effect making the deprotonated nitrogen atoms stronger sigma 
donors thus stabilizing the complexes more effectively. The ligands and complexes are mainly 
varied by the structures of the di(azomethine) linkage, by adjusting the structure of this group 
the solubility profile (i.e. the lipophilicity) can be tuned. The ability of the complex to cross the 
phospholipid bilayer and reach its intended cellular target (DNA) can therefore be optimised. 
3.2 Synthesis of the Schiff Base Ligand  
3.2.1 Synthesis of H2L1- H2L8 
The synthesis of these ligands involved a simple condensation reaction between an imidazole 






















Ligand R1 X 
H2L1 CH3 CH2CH3CH2 
H2L2 CH3 CH2CH2(CH3CH3)CH2 
H2L3 H CH2CH3CH2 
H2L4 CH3 CH2CH2(OH)CH2 
H2L5 CH3 CH2CH2CH2CH2 
H2L6 CH3 R,R-cyclohexyl 
H2L7 CH3 S,S-cyclohexyl 
H2L8 CH3 CH2CH2 
 
Scheme 3.2.1: Condensation reaction for the synthesis of H2L1-H2L8. 
The above reactions all involve the condensation of an aldehyde with a primary alkyl amine. The 
structure of the alkyl amine bridging unit did not have any notable influence on the efficiency of 
the reaction and a single method was therefore applied in the synthesis of H2L1 - H2L8. 
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3.2.2 Synthesis of H2L9 and H2L10 
 
For the synthesis of ligand H2L9 and H2L10 the ethoxy bridging unit and methoxy bridging unit 
respectively had to be synthesised from 1,3-diamino-2-propanol. The hydroxyl group on the 
second carbon can be easily derivatised. Before the hydroxyl group can be converted, the 
primary amines need to be protected with di-tert-butyl dicarbonate (Boc2O) as primary amines 
(pKa= 10-11) are more reactive than alcohols (pKa=16.5) [3]. Scheme 3.2.2 below shows the 
conversion of the primary amines to amides resulting in them being less nucleophilic and thus 





























Scheme: 3.2.2: The protection of primary amines using di-tert-butyl dicarbonate. 
The newly formed amine bond formed exhibits resonance. In the resonance form the amine is 






















Scheme: 3.2.3: The different resonance forms of the protected diamine. 
After protection, the hydroxyl group is converted to an ether with the addition of an alkyl iodide 
in the presence of [Bu4N][HSO4] and 50% NaOH. The hydroxyl group is deprotonated leading to 
an SN2 type reaction with the alkyl halide resulting in the formation of the ethoxy and methoxy 
groups. The [Bu4N][HSO4] acts as a phase transfer catalyst in the biphasic reaction mixture. It 
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carries hydroxide ions from the aqueous to the organic layer allowing deprotonation of the 



























Scheme 3.2.4: SN2 type reaction of the hydroxyl group. 
After the formation of the ether the amines are deprotected by the addition of excess HCl. This 























Scheme 3.2.5: Deprotection reaction to form hydrochloride salt. 
The acidity of the hydrochloride salt was found to hinder the condensation reaction therefore  
2-ethoxy-1,3-diamino-2-propane was synthesised via a solid state reaction by grinding 2-
ethoxy-1,3-diamino-2-propane dihydrochloride and sodium carbonate in an agate pestle and 
mortar. Once the 2-ethoxy-1,3-diamino-2-propane was formed 4-methyl-1H-imidazole-5-
carbaldehyde was added to the mortar and the two were ground together in the presence of 
piperidine which was used as a catalyst. The solid-state method proved to be very effective with 
high yields and short reaction times. The method also conforms to modern green chemistry 




3.3 Metallation of Schiff Base Ligands 
3.3.1 Gold(III) salts  
 
As a source of gold(III) ions, the tetra-butylammonium tetrachloroaurate ([Bu4N][AuCl4]) was 
used. Although Na[AuCl4], H[AuCl4] are also viable sources of gold(III) ions [4][5], they have 
been associated with the formation of unwanted [AuCl4]- or [AuCl2]- counter ions when isolating 
cationic metal chelates. The drawbacks of these gold-based anions are that it leads to a poor 
aqueous solubility, making characterization difficult. Secondly if a gold counter ion is formed 
only half of the moles of gold go towards forming the complex. H[AuCl4] has been reported as an 
efficient source of gold(III) ions for chelation by N-donor ligands. This is dependent on the 
nature of the N-donor ligands as some research states that the salt is favoured as it lowers the 
pH of the solution which aids the chelation. In some cases where ligand deprotonation is 
required, the lower pH hinders this process preventing metal chelation [5][6][7][8]. 
 Previous reactions have attempted to use Na[AuCl4] or H[AuCl4] as a gold(III) ion source at 
varying temperatures. The reactions were unsuccessful resulting in black precipitate (Au2O3) or 
colloidal gold [9].  
Barnholtz et al. concluded that [Bu4N][AuCl4] is the most effective gold salt from the three 
mentioned. For a successful reaction with the [Bu4N][AuCl4] salt it requires the presence of a 
hexafluorophosphate(V) salt and ethanol. If one of the two are not present the reaction fails. The 
reagents seem to pay a role in breaking the [Bu4N][AuCl4] ion pair[5]. 
An added advantage of using [Bu4N][AuCl4] is that it is lipophilic and dissolves in non-polar 
organic solvents, whereas the target cationic gold(III) chelates are soluble in polar organic 
solvents therefore the gold chelates precipitate out of solution simplifying the required reaction 
workup. 
3.3.2 Metallation of H2L1, H2L2 and H2L10 
 
Metallation of free ligands H2L1, H2L2 and H2L10 were successful using [Bu4N][AuCl4]. The 
ligand was dissolved in ethanol while the [Bu4N][AuCl4] was dissolved in DCM. The two 
solutions were added and the relative complex precipitated out of solution.  The three resulting 
complexes contain a PF6- counter ion. Scheme 3.3.2.1 shows the general metalation of ligands 



































Scheme 3.3.1: General reaction outline for metalation of ligands H2L1, H2L2 and H2L10. 
Table 3.3.1: Summary of R groups of different ligands. 
Ligand  R1 R2 
AuL1 H H 
AuL2 CH3 CH3 
AuL10 H OCH3 
 
3.3.3 Metallation of H2L4 and H2L9 
 
Metallation of free ligands H2L4 and H2L9 were successful using [Bu4N][AuCl4]. The ligand was 
dissolved in ethanol while the [Bu4N][AuCl4] was dissolved in DCM.  Complex [Au(L4)Cl-] 
precipitated out of solution while [Au(L9)Cl-] remained in solution. The solution containing 
[Au(L9)Cl-] had the solvent  removed via rotary evaporation and was washed with THF. Both 
these complexes have a Cl- counter ion also [Bu4N][PF6] was added to the reaction. Scheme 




































Scheme 3.3.2: General reaction outline for metalation of ligands H2L4 and H2L9. 
Table 3.3.2: Summary of R groups of different ligands. 
Ligand  R1 R2 
AuL4 H OH 
AuL9 H OCH2CH3 
 
3.3.4 Metallation of H2L3, H2L5, H2L6, H2L7 and H2L8 
 
Metalation of ligands H2L3, H2L5, H2L6, H2L7 and H2L8 was unsuccessful using the above 
method. The reaction was carried out with 2 molar equivalents of ligand, but no metal ion 
chelation could be detected.. The possible reason for the failure of the metallation is the 
 two-carbon bridging units creating a small coordination site for the large gold(III) ion. 
Considering that all the ligands which have a three carbon bridging unit easily coordinated the 
gold(III) ion it can be concluded that for this system a three-carbon bridge leading to two five-
membered and a six-membered chelation rings  is ideal.  
In conclusion, seven novel Schiff base ligands and five novel gold(III) Shiff base chelates were 
successfully synthesized. The ligand synthesis gave consistently good yields and the metallation 
reactions resulted in decent yields except in AuL9 where the yield was low due to the complex 
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Chapter 4| Spectroscopy 
4.1 Infrared spectroscopy  
4.1.1 Introduction  
 
The bonds in molecules are continuously stretching and bending. Stretching occurs along the 
bond line while bending changes the bond angle [1]. Molecules that have covalent bonds have 
the ability to absorb light in the infrared region (700 mm – 1 mm). The region of greatest 
interest is 2500 nm – 25000 nm (400 to 4000 cm-1) which is the region for vibrational 
transitions. The molecule absorbs the infrared radiation which results in transitions between 
the vibrational and ground state energy levels. These transitions are presented as an IR 
spectrum [1]. 
The total energy of a molecule comprises the movement of electrons in the molecules, the 
vibrations of each atom in the molecule and rotation of the molecule. Analysis can be performed 
by measuring absorption, emission and reflection. This technique is used to determine the 
functional groups present in the compound as different functional groups vibrate at different 
stretching frequencies (wavenumbers). In general, stronger bonds (i.e. higher bond orders) 
vibrate at higher wavenumbers [2]. 
One of the key stretching frequencies that will confirm a successful Schiff base condensation is 
the imine C=N stretch. This bond will typically have a stretching frequency in the region of  
1680 cm-1.   
4.1.2 Results and discussion  
 
The most significant band in the IR spectrum of a Schiff base ligand is the imine (C=N) group 
which is found in the range of 1690 – 1640 cm-1 [1]. When chelated to the gold(III) ion there is a 
considerable spectral shift to lower wavenumbers of the imine C=N stretching frequency. This is 
due to the strongly electron withdrawing metal ion removing electron density from the 
coordinated imine nitrogen atom and weakening the double bond. The imine stretching 
frequencies of the imine groups for the free ligands and gold(III) chelated ligands are 
summarised in Table 4.1.1. 
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Table 4.1.1: Imine stretching frequencies of the free ligands and gold(III) chelates. 
Schiff base  Free Ligand (cm-1)  Gold(III) Chelate (cm-1)  
H2L1   1645    1597 
H2L2   1646    1597 
H2L3   1648                                N/A 
 
H2L4   1648    1598 
H2L5   1645    N/A 
H2L6   1634    N/A 
H2L7   1645    N/A 
H2L8   1635    N/A 
H2L9   1646    1597 
H2L10   1645    1598 
 
 
The data in Table 4.1.1 clearly show that the imine stretching frequencies of the free ligands are 
higher than those of the gold(III) chelates.  The decrease in stretching frequency is due to the 
electron density moving from the ligand to the gold(III) ion. The data summarised in Table 4.1.1 
also show that all the ligands have similar imine stretching frequencies. This suggests that the 
substitution on the alkyl bridging unit has little influence on the vibrational energy of the 
relatively remote imine bond.   
The frequency of an NH stretching band is typically in the region of 3500-3300 cm-1, but the NH 
bands observed herein are at lower frequencies [3]. This is likely due to hydrogen bonding 
between the imidazole NH and imine nitrogen atom (vida infra). This hydrogen bonding motif is 
illustrated in Chapter 5 and is a common feature of imidazole- and pyrrole-based Schiff base 
ligands. This electrostatic intermolecular interaction results in a lower force constant for the 
pyrrole NH, therefore lowering the vibrational frequency. Table 4.1.2 summarises the NH 
stretching frequencies for each free ligand. This band is not evident in the IR spectra of the 








Table 4.1.2: Imdazole NH stretching frequencies for the free ligands. 












Ligand H2L4 and complex [Au(L4)](PF6) have OH stretching frequencies at 3587 and 3365 cm-1, 
respectively. These values correlate with typical OH stretches [13]. There are also C-O 
stretching frequencies for H2L4 and [Au(L4)](PF6)  found at 987 and 970 cm-1, respectively. 
The IR spectra of the ligands differ from those of the complexes in two key ways. The first is the 
absence of the pyrrole NH peak in the complexes, which indicates chelation and secondly the 
decreasing of the C=N stretching frequencies upon chelation. The IR spectra for the metal 
chelates with the PF6 anion also have a strong band at 826 nm which correlates to the P-F 
stretch [18]. The vibrational frequencies of these key functional groups are illustrated in Figures 
4.1.1 and 4.1.2 which show the IR spectra of the H2L2 and [Au((L2)](PF6), respectively as 
representative examples.  
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Figure   4.1.1: IR spectrum of ligand H2L2. 
 
Figure 4.1.2: IR spectrum of complex [Au(L2)](PF6). 


































4.2 UV/visible spectroscopy  
4.2.1 Introduction 
 
The energy of ultraviolet and visible light (200 nm-800 nm) is sufficient to cause an electronic 
transition within a molecule. Depending on the amount of energy needed for the transition 
either ultraviolet or visible light will be absorbed [1].  
When a molecule is in its ground state, all electrons are in the lowest energy molecular orbitals. 
When the molecule absorbs a photon of light the electrons move to a higher energy molecular 
orbital, the electron is now excited. This is called an electronic transition. Figure 4.2.1 illustrates 
the different transitions possible for an electron. 
 
Figure 4.2.1: Diagram showing possible electronic transitions [2]. 
 
Using a UV/visible spectrophotometer the transmittance can be measured which is the fraction 
of original light passing through the sample. The absorbance can be calculated using: 
A = log (
Io
I
) = −logT...(1) 
In the above equation A is absorbance, Io is intensity of applied energy, I is the resultant energy 













σ σ- * n- *σ
π π- * n- *π
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All free aromatic ligands will exhibit an intense π-π* transition and a much weaker n-π* 
transition. Both these transitions will fall into the range of 270-320 nm [5][6]. When the free 
ligands are chelated to the gold(III) ion there will be a new absorption band expected in the 
region of 400-450 nm [6]. This new band is common for square planar metal complexes of late 
transition metal ions, and are ligand to metal charge transfer (LMCT) bands. Due to the high 
oxidation state of the gold(III) ion metal-to-ligand charge transfer (MLCT) is not possible [5]. 
 
4.2.2 Results and discussion  
 
Figures 4.2.2 and 4.2.3 show the UV/visible spectra of H2L2 and [Au(L2)](PF6) as representative 
examples of the free ligands and gold(III) chelates reported herein. 
 
Figure 4.2.2: Electronic spectrum of H2L2 in methanol showing a π-π* transition. An n-π * 
transition is evident as a shoulder at approximately 306 nm. 
Figure 4.2.2 shows a single peak at 267 nm. This peak corresponds to the π-π* transition 
characteristic of the free ligands; a result of their extended conjugation. This peak is typical for 
Schiff base ligands both when chelated to metals and as free ligands. Although the π-π* 
transition peak dominates the spectrum there is a second electronic band present as a shoulder 





































of the main band. This is the n-π* transition. This transition, seen at 306 nm, is significantly less 
intense than the π-π* transition and is responsible for the pale yellow appearance of the 
compound in solution. 
 
Figure 4.2.3: Electronic spectrum of [Au(L2)](PF6) in DMSO showing an LMCT and π-π*  
transition. 
The UV/vis spectrum of [Au(L2)](PF6) shows two peaks. The first transition is at 261 nm and is 
the π-π* transition as noted in the ligand, but it has a small bathochromatic shift when 
compared to the free ligand. The second peak is found at 342 nm and is due to the chelation of 
the gold(III) ion by the free ligand. The transition involves the transfer of electrons between the 
ligand and gold(III) metal centre : ligand-to-metal charge transfer (LMCT). Since the gold ion is 
in a high oxidation state metal-to-ligand charge transfer is not possible. The symmetry of the 
orbitals involved in the LMCT band is discussed in Chapter 6. 
A summary of the extinction coefficents of the free ligands and gold(III) chelates is shown in 
Table 4.2.1.  
 
 































LMCT band at 342 nm




Table 4.2.1: Extinction Coefficients for the free ligands and gold(III) chelates. 
Free 
Ligand 
λ (nm) Extinction 
Coefficient 
(M-1 cm -1) 
Gold(III) 
Chelate 
λ (nm) Extinction Coefficient 
(M-1 cm -1) 
H2L1 266 2.01 × 104 [Au(L1)](PF6) 270, 339 3.59 × 104 1.47 × 104 
H2L2 267 1.35 × 105 [Au(L2)](PF6) 261, 342 1.91 × 104 2.62 × 104 
H2L3 274 9.00 × 104 [Au(L3)](PF6) N/A N/A N/A 
H2L4 268 1.37 × 105 [Au(L4)](Cl) 265, 339 2.59 × 104 2.06 × 104 
H2L5 265 3.00 × 104 [Au(L5)](PF6) N/A N/A N/A 
H2L6 260 2.11 × 104 [Au(L6)](PF6) N/A N/A N/A 
H2L7 268 2.40 × 104 [Au(L7)](PF6) N/A N/A N/A 
H2L8 265 2.30 × 104 [Au(L8)](PF6) N/A N/A N/A 
H2L9 266 1.10 × 104 [Au(L9)](Cl) 267, 331 2.82 × 104 1.11 × 104 
H2L10 266 1.21 × 104 [Au(L10)](PF6) 267, 340 2.54 × 104 5.07 × 103 
 
The data summarised in Table 4.2.1 show that all the ligands and gold(III) chelates have similar 
extinction coefficients. This suggests that the absorption spectra are dominated by the aromatic 











4.3 NMR spectroscopy  
4.3.1 Introduction  
 
Nuclear magnetic resonance (NMR) spectroscopy is the most commonly used characterization 
technique. NMR is easy to run, has wide application and provides a large amount of structural 
information. It was developed in the 1940’s by physical chemists studying atomic nuclei, but in 
1951 it was found NMR could be used to study organic structures. Atoms that have an odd 
number of protons or odd number or neutrons or both possess a property know as spin [7].  
Due to its charge and spin, the nucleus has a magnetic moment. Without an external magnetic 
field the magnetic moments of the nuclei are randomly arranged, but in the presence of an 
external magnetic field the nuclei are ordered. The nuclei either align with or against the 
magnetic field. The nuclei that align with the magnetic field are in a lower energy state (α-spin) 
and the nuclei that align against the magnetic field are in a higher energy state (β-spin) [7]. 
When a pulse of electromagnetic radiation is delivered to the nuclei the α-spin states are 
promoted to the higher energy state and become β-spin states. This conversion is referred to as 
flipping. The energy supplied is in the radio frequency (rf) (3 kHz - 300 GHz) range. When 
flipping occurs a signal is generated whose frequency is proportional to the difference in energy 
from α-spin state to β-spin state [7].  
The most common nuclei studied are 1H, 13C, 19F and 31P. This is because these isotopes have a 
spin quantum number of  
1
2
  and, with the exception of 13C, the NMR-active isotopes have a high 
natural abundance [8]. Although the gold(III) nucleus is diamagnetic, 197Au NMR is not possible. 
This is due to the large quadrupole moment of the nucleus, which places it outside the range of 








4.3.2 Results and discussion  
 
The 1H and 13C NMR spectra of H2L9 and [Au(L9)](PF6) are shown in Figures 4.3.1 to 4.3.4 as 
representative examples of the NMR spectra of the free ligands and gold(III) chelates. 
 
 
Figure 4.3.1: 1H NMR spectrum of the free ligand H2L9. 
 



























































Figure 4.3.3: 13C NMR spectrum of free ligand H2L9. 
 
Figure 4.3.4: 13C NMR spectrum of complex [Au(L9)](PF6). 
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Table 4.3.1: A summary of the chemical shifts of the 1H NMR for H2L9 and [Au(L9)](PF6). 
Proton H2L9 (ppm) [Au(L9)](PF6) (ppm) 
CH2CH(OCH2CH3)2CH2 1.02 1.10  
CH2CH(OCH2CH3)2CH2 2.08 2.54 
Methyl 2.31 3.57 
CH2CH(OCH2CH3)CH2 3.54 3.95 
CH2CH(OCH2CH3)CH2 3.70 4.37 
Imidazole CH 7.52 8.44 
Imine 8.20 8.95 
Imidazole NH 12.18 N/A 
 
When comparing the 1H NMR spectra of the free ligand and corresponding gold(III) chelate 
there is an overall downfield shift observed. The imine hydrogen experiences the largest 
downfield shift which is attributed to the strong deshielding effect of the metal ion. The smallest 
downfield shift is experienced by the methyl hydrogen atoms of the ethyl ether group which is 
due to the group being remote to the metal centre. The spectrum indicates a general 
polarisation of the ligand by the gold(III) Lewis acid. The 1H NMR assignments for the remaining 
free ligands and metal chelates are reported in Chapter 2. 
A comparison of the chemical shifts of the 13C NMR spectra for H2L9 and [Au(L9)](PF6) is shown 
in Table 4.3.2.  
Table 4.3.2: A summary of the chemical shifts of the 13C NMR spectra for H2L9 and 
[Au(L9)](PF6). 
Carbon H2L9 (ppm) [Au(L9)](PF6) (ppm) 
Methyl 10.00 14.60 
CH2CH(OCH2CH3)CH2 14.39 15.60 
CH2CH(OCH2CH3)CH2 62.29 53.27 
CH2CH(OCH2CH3)CH2 65.17 63.97 
CH2CH(OCH2CH3)CH2 78.79 75.16 
1 128.07 134.59 
3 137.38 148.01 
4 142.32 152.97 




The 13C data show that the carbon bonded to the imine has the largest downfield shift while the 
bridging unit carbons do not experience a significant downfield shift as they are the furthest 
from the gold(III) ion. This downfield shift is again due to the deshielding effect of the chelated 
gold(III) metal ion.  The methoxy and ethoxy groups do influence the shifts as they are electron 
donating groups. The 13C NMR assignments for the remaining free ligands and metal chelates 
are reported in Chapter 2. 
The 19F and 31P NMR spectra of [Au(L10)](PF6) are shown in Figures 4.3.5 and 4.3.6 as 
representative examples of heteronuclear NMR spectra of the gold(III) chelates. These spectra 
are used to confirm the identity of the counter anion in conjunction with X-ray crystallography. 
This is important as cationic gold(III) chelates are known to readily form as the 
tetrachloroaurate(III) and dichloroaurate(I) complex salts. 
 
Figure 4.3.5: 19F NMR spectrum of complex [Au(L10)](PF6). 
In the 19F NMR spectra a large doublet is observed indicating coupling between the 




Figure 4.3.6: 31P NMR spectrum of complex [Au(L10)](PF6). 
In the 31P NMR spectra, seven lines are observed indicating that six fluorine atoms are bonded 
to the phosphorus atom. By using 19F and 31P NMR techniques it is possible to prove that the 
counter ion is indeed PF6. 
4.4 DNA binding studies 
4.4.1 Introduction  
 
DNA is responsible for many aspects of life such as controlling the function of cells. DNA is an 
important target for a large range of anticancer drugs [10]. The novel gold(III) chelates 
synthesised in this study are designed to be targeted DNA intercalating chemotherapeutic 
agents. This intercalation will in inhibit DNA replication resulting in apoptosis [11]. For a metal 
complex to intercalate it is required to have two vital features: 
1. A planar aromatic region which allows the metal complex to insert between DNA base 
pairs.  
2. The metal complex must have an overall cationic charge. This is required to interact 




Chelate [Au(L4)](PF6) is expected to form hydrogen bonds with DNA as it has an OH functional 
group on the bridging unit. This hydrogen bond could potentially further stabilise the DNA/drug 
conjugate. 
In this study, two methods were employed to determine the binding affinity of the gold(III) 
chelates. The first is a direct binding method and the second is a competitive binding method.  In 
the direct binding method the binding constant is determined by monitoring the absorption 
spectrum of the metal chelate as a function of calf thymus DNA (ctDNA) concentration. The 
ctDNA is intercalated by the metal chelate thus lowering the effective concentration of the metal 
chelate in solution typically leading to both hypochroism and a bathochromic shift. The binding 
constant is calculated by using the change in absorption as a function of the concentration of 
ctDNA [14]. 
In a competetive binding experiment a second, known DNA intercalating compound is used, in 
this case ethidium bromide (EB). EB and ctDNA both have weak florescence, but when EB 
intercalates ctDNA it has strong florescence. This large change in florescence is due to the 
nucleic acids which absorb UV light (260 nm) and then passes on this energy to EB [15]. By 
introducing the metal chelate (the second intercalator) the florescence emission of ctDNA 
intercalated by EB can be quenched as the metal chelate replaces the intercalated EB [16]. By 
monitoring the emission spectrum of the EB/DNA conjugate as a function of metal chelate 
concentration it is possible to determine an apparent binding constant. 
 
4.4.2 Experimental  
 
The stock ctDNA that was used in all DNA binding experiments was purchased from Sigma 
Aldrich (Germany). 
For direct binding a phosphate buffer was prepared using monosodium phosphate and 
disodium phosphate.  The final ionic strength of the solution was 0.1 M. The pH of the buffer 
solution was raised to the required 7.1 using a concentrated NaOH solution. The buffers were 
prepared and the experiments preformed at 37˚C to mimic the mammalian cellular 
environment.   
The masses of the acid and base required were calculated using the Henderson-Hasselbach 






Two cuvettes were used; one as a reference and the second for the sample. The reference 
cuvette contained only 10% DMSO and 90% phosphate buffer while the second cuvette 
contained DMSO, phosphate buffer and metal complex, at a concentration of approximately  
2 × 10-5 M . Aliquots of DNA were added to both cuvettes to account for the absorbance of the 














 … (2) 
 





εa = Extinction coefficient of the EB band at given [ctDNA] 
 εf = Extinction coefficient of free EB 
 εb = Extinction coefficient of fully intercalated EB 
 Kb = Equillibrium binding constant in M-1 
 Ct = Total concentration of ctDNA 
 s = Binding site size 
For competitive binding a 25 mM tris-HCl buffer was prepared using ulta-pure water. This 
solution was adjusted to pH 7 using 1 M HCl. The ctDNA was dissolved in the buffer solution and 
the concentration was determined spectroscopically using an extinction coefficient of  
13200 M-1cm-1 per base pair. A solution of 15 μM ctDNA and 15 μM EB was prepared with 15% 
DMSO in the tris-HCl buffer. Gold(III) chelate stock solutions were also prepared in DMSO. 
Aliquots of the gold(III) chelate solution were added to the ctDNA-EB solution. The emission of 
the sample was recorded between 530 nm and 800 nm using an excitation wavelength of  
500 nm after each addition. The apparent binding constant is calculated using equation 3. 
𝐾𝑎𝑝𝑝 [𝑐𝑜𝑚𝑝𝑙𝑒𝑥] =  𝐾𝐸𝐵[𝐸𝐵]… (3) 
Where: 𝐾𝐸𝐵 = binding constant of EB to ctDNA 
 [𝐸𝐵] = molar concentration of EB 
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 [𝑐𝑜𝑚𝑝𝑙𝑒𝑥] = concentration of the gold(III) chelate that causes a 50% quenching of the           
initial EB fluorescence (C50) 
Io (initial fluorescence intensity) is determined from a non-linear squares fit of the change in EB 
emission at 615 nm and f(x), with the concentration of the metal chelate, x, to equation 4. 
𝑓(𝑥) =  
𝐼𝑜 × 𝐶50
𝑥+ 𝐶50
 … (4) 





















4.4.3 Results and discussion   
 
Determination of the ctDNA binding constants was first attempted for all five gold(III) chelates 
by direct titration using different concentrations of ctDNA and gold(III) chelate. Signs for 
successful intercalation include a decrease in absorption intensity and a bathochromic shift. 
These signs are a result of a decrease in concentration of metal complex in solution as it 





Figure 4.4.1: Absorption spectrum of [Au(L1)](PF6) with increasing concentrations of ctDNA. 
Figure 4.4.1 initially suggests an interaction between the metal complex and ctDNA. However, if 
the dilution effects of the addition of the aliquots of DNA are accounted for then it is clearly 
evident that there is no detectable DNA binding. The spectra also show no isosbestic point, 
which is usually associated with a change of species in solution. The ctDNA has an absorption 
maximum at 260 nm. It is believed that the absorption of the ctDNA may obscure the 
absorbance of the metal chelate (lambda max at 330 nm) thus masking the spectroscopic 
changes associated with intercalation. This leads to a negative result. To solve this issue, a 
competitive binding experiment was employed as this is independent of the UV/visible 
absorption properties of the metal chelate.  
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Competitive binding was attempted with different concentrations of ctDNA and gold(III) 
chelate, but again only the dilution effect was observed. This lead to the conclusion that the 
gold(III) chelates in this study are very weak DNA intercalators. This is likely due to the two 
methyl groups on the imidazole rings. The methyl groups would cause steric hinderence and 
prevent the gold(III) chelate from intercalating between DNA base pairs. The failure to 
synthesise [Au(L3)](PF6) shows that as the inductive effect of the methyl groups is required to 
stabilise the gold(III) ion. A possible way around this obstacle is to move the position of the 
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Figure 4.4.3: Proposed structure for gold(III) chelates that would likely improve DNA 
intercalation. 
By using 1-(1H-imidazol-5-yl)ethanone instead of 4-methyl-1H-imidazole-5-carbaldehyde, it 
will create a larger planar aromatic region for intercalation while still obtaining the inductive 









1. Bruice, P. Organic Chemistry; 6th ed.; Prentice Hall: Upper Saddle River, N.J., 2010; pp. 
115-120. 
2. Pavia, D. Introduction to spectroscopy; Brooks/Cole, Cengage Learning: Belmont, CA, 
2009. 
3. R. M. Silverstein; Spectrometric identification of organic compounds. 7th ed.; John Wiley 
& sons: Hoboken, NJ, 2005. 
4. Brisdon, A. Inorganic Spectroscopic Methods; Oxford University Press: Oxford, 1998. 
5. Comas-Vives, A.; González-Arellano, C.; Corma, A.; Iglesias, M.; Sánchez, F.; Ujaque, G. J. 
Am. Chem. Soc. 2006, 128, 4756-4765. 
6.  Yamada, S.Yamanouchi, K. Bull. Chem. Soc. of Jpn., 1970, 43, 1744-1746. 
7. Bruice, P. Organic Chemistry; 6th ed.; Prentice Hall: Upper Saddle River, N.J., 2010; pp. 
115-120. 
8.  Hore, P. Nuclear Magnetic Resonance; Oxford University Press: Oxford, 1995. 
9. Akerman, M. P., Structural physical and biological studies of gold(III) Bis(Pyrrolide-Imine) 
Schiff base complexes : potential chemotherapeutic agents, University of KwaZulu Natal, 
2011.  
10. Rehman, S. U., Yaseen, Z., Husain, M. A., Sarwar, T., Ishqi, H. M. and Tabish, M.; PLoS ONE 
2014, 9 (4), 1-11. 
11. Munro, O. Q., Akerman, K. J. and Akerman, M. P. Gold Complexes for Use in the Treatment 
of Cancer. US Patent 20,130,090,472. 2013. 
12. Zeglis, B. M., Pierre, V. C. and Barton, J. K.; Chem. Commun. 2007, 44, 4565-4579. 
13. Ke-Liu, H. and Sadler, P. J.; Acc. Chem. Res., 2011, 44 (5), 349-359. 
14. Chen, L.; Liu, J.; Chen, J.; Tan, C.; Shi, S.; Zheng, K.; Ji, L. J. Inorg. Biochem.,2008, 102, 330-
341. 
15. LV, Y.-K., Li, P., Jiao, M.-L., Liu, B. S. and Yang, C.; Turk. J. Chem. 2014, 38, 202-209. 
16. Garcia-Gimenez, J. L., Gonzalez-Alvarez, M., Liu-Gonzalez, M., Macias, B., Borras, J. and 
Alzuet, G.; J. Inorg. Biochem 2009, 103, 923-934. 
17. Barnholtz, S. L., Lydon, J. D., Huang, G., Venkatesh, M., Barnes, C. L., Ketring, A. R. and 












Chapter 5| X-Ray Crystallography 
5.1 Introduction  
5.1.1 Previously reported ligands  
 
A total of ten bis(imidazole-imine) ligands were synthesised in this project, two of which have 
been crystallised and studied by single crystal X-ray diffraction. A Search of the Cambridge 
Structural Database (CSD) [1] shows very few bis(imidazole-imine) compounds have been 
studied by single crystal X-ray diffraction. Related structures which have a common bridging 
unit to those studied in this work are summarised in Table 5.1.1. the structure of the 
compounds are illustrated in Figure 5.1.1. 
Table 5.1.1: Reported X-ray structures of similar bis(imidazole-imine)ligands 
CSD Ref. 
Code 













The X-ray structures reported in Table 5.1.1 exhibit structural similarities to those studied by  
X-ray crystallography in this work. The similarities include methyl-imidazole rings (in some 





Figure 5.1.1: Partially labelled X-ray structures of (a) DAZXOS (b) XUVQAG (c) EFAROU 
(d)WOBNAD. 
N-(pyridin-2-ylmethylene)-N’-(pyridin-4-ylmethylene) cyclohexane-1,2-bis-imine (DAZXOS) 
crystallized in the monoclinic space group C2/c. The ligand exhibits a one-dimensional 
supramolecular network. The one-dimensional network is stabilised by two unique hydrogen 
bonds between the imine N (H-bond acceptor) of one molecule and the imidazole NH atom  
(H-bond donor) of an adjacent molecule (N1···H1=2.00(1); N1···N3=2.944(1)Å) as shown in 





Figure 5.1.2: One-dimensional network of DAZXOS stabilised by hydrogen bonds between the 
imine N atoms and the imidazole NH atoms of adjacent molecules in the solid state. 
N,N’-cyclohexylenebis(pyrrol-2-ylmethyleneamine) (XUVQAG) crystallised in the P22121 space 
group. Significant bond lengths are summarised below in Table 5.1.2 
Table 5.1.2: Summarised bond lengths for XUVQAG. 







It is important to note that this compound crystallises as the hydrate with a single water 
molecule associated with each ligand molecule. The water molecule acts as both a hydrogen 
bond acceptor and hydrogen bond donor, bridging adjacent ligand molecules. This hydrogen 
bonding motif leads to a one-dimensional supramolecular structure co-linear with the c-axis. 
The pyrrole NH and imine N atoms act as hydrogen bond donors and acceptors, respectively 
bonding to the water molecule. This geometry leads to two unique hydrogen bonds. The bond 
parameters are summarised in Table 5.1.3. The hydrogen-bonded supramolecular structure is 






Table 5.1.3: Hydrogen bond lengths (Å) and bond angles (˚) of XUVQAG. 
D-H···A D-H H···A D···A D-H···A 
O···N2 1.05 1.76(4) 2.783(3) 164.2 
O···N1 0.91(3) 2.00(2) 2.868(2) 159.6 
 
 
Figure 5.1.3: Structure of XUVQAG stabilised by hydrogen bonds between the water molecule 
and imine N atoms and the pyrrole NH groups of adjacent molecules in the solid state. 
Compound EFAROU crystallised in the monoclinic space group, P21/n as the dihydrate with and 
two water molecules in the asymmetric unit as shown in Figure 5.1.4. Both molecules have 
similar conformations with an root mean square deviation of 0.242 Å highlighting the similarity. 
The two water molecules bridge the two ligand molecules through a similar hydrogen bonding 
motif to that described above. The asymmetric unit is therefore an unusual example of a 
hydrogen-bonded heterotetramer stabilised by eight unique hydrogen bonds. The bridging 
water molecule acts as both a hydrogen bond acceptor and donor. The hydrogen bond 
parameters are summarised in Table 5.1.4. The mean imine bond lengths are 1.270(4) Å, 








Table 5.1.4: Hydrogen bond parameters (Å,˚) for EFAROU. 
D—H···A D—H H···A D···A D—H···A 
O1W—H1W···N3A 0.82 (3) 2.28 (3) 3.014 (2) 149 (3) 
O1W—H2W···N3B 0.92 (3) 1.96 (3) 2.857 (2) 166 (3) 
O2W—H3W···N2B 0.80 (3) 2.16 (3) 2.927 (2) 159 (3) 
O2W—H4W···N2A 0.98 (3) 1.88 (3) 2.819 (2) 159 (2) 
N1A—H01A···O2W 0.93 (2) 2.03 (2) 2.896 (2) 154 (2) 
N1B—H01B···O2W 0.95 (2) 1.96 (2) 2.899 (2) 169 (2) 
N4A—H04A···O1W 0.88 (2) 2.02 (2) 2.882 (3) 166 (2) 
N4B—H04B···O1W 0.86 (3) 2.09 (3) 2.896 (3) 155 (2) 
 
 
Figure 5.1.4: Heterotetrameric structure of EFAROU stabilised by hydrogen bonds between the 
water molecules and imine N atoms and pyrrole NH groups. 
WOBNAD crystallised in the Fddd space group with a half molecule in the asymmetric unit and  
Z = 16. WOBNAD is the only example of a free ligand derived from methyl imidazole, such as 
those in this work, to be studied by single crystal X-ray crystallography. There are two unique 
hydrogen bonds stabilising the solid state structure. The nitrogen atoms act as a hydrogen bond 
acceptors and the NH groups hydrogen bond donors. The hydrogen bond parameters are 
summarised in Table 5.1.5. These hydrogen bonds give rise to a two-dimensional network as 
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shown in Figure 5.1.5. The network comprises one-dimensional chains, which are linear, these 
are cross-linked through hydrogen bonds to adjacent chains at an angle of ca. 134.1˚.  
Table 5.1.5: Hydrogen bond parameters (Å,˚) for WOBNAD. 
D-H···A D-H H···A D···A D-H···A 
N3–H3···N3 0.861 2.035 2.885(5) 169.2 
N1–H1···N1 0.860 2.010 2.836(4) 160.8 
 
 
Figure 5.1.5: Two-dimensional hydrogen-bonded network structure of WOBNAD stabilised by 
hydrogen bonds between the imidazole N atoms and the imidazole NH atoms of adjacent 
molecules in the solid state. 
 
5.1.2 Previously reported metal chelates 
 
Three of the synthesised gold(III) chelates have been crystallised and studied by single crystal 
X-ray diffraction. A search of the Cambridge Structural Database (CSD)[1] shows very few 
gold(III) chelates with related ligands have been previously reported. The few relevant 








Table 5.1.6: Reported X-ray structures of related gold(III) chelates. 
CSD Ref. 
Code 












quinoxalinato]gold(III) hexafluorophosphate(V) mono 
(acetonitrile) solvate 
6 


























Table 5.1.6: Continued. 











The X-ray structures reported in Table 5.1.6 exhibit similar structural features to those 
synthesised in this work. The similarities include square planar gold(III) ions, tetradentate 
ligands joined through imine bonds and with three carbons acting as a bridging unit. Several of 
the ligands coordinated to gold(III) in this work have been chelated to various metals. These 




Figure 5.1.6.: Partially labeled structure of (a) RIZHAL (b) RIZHEP (c) RIZHIT (d) RAVHIG 
(e)BAQHEG (f) MAYQIM (g) MAYQOS (h) MAYQUY (i) BAGHAT (j) KURQAR (k) GASQEW. 
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Compound RIZHAL crystallised in the Monoclinic, P2/c space group. RIZHAL has a square 
planar coordination geometry , this is a result of the vacant dx2-y2 orbitals of the d8 metal ion. 
The gold(III) ion is displaced slightly above the mean plane defined by the the aromatic rings. 
Relevant bond angles and bond lengths are summarised in Table 5.1.7. The bridging unit shows 
a characteristic out-of-plane distortion to accommodate the sp3 hybridised carbon atoms of the 
di(azomethine) linkage. 
Table 5.1.7: Summary of bond lengths and bond angles describing the coordination sphere of 
RIZHAL. 
Bond Bond length (Å) Bond angle(˚) 
Average Au-Nimine 2.013   
Average Au-Npyrrole 1.9845   
Nimine -Au-Nimine  97.22 
Nimine -Au- Npyrrole  81.77 
Npyrrole -Au- Npyrrole  99.20 
 
 Weak C-H···F interactions between the methylene hydrogen atoms and the fluorine atoms of 
the counter ion lead to a one-dimensional supramolecular structure co-linear with the c-axis. 
The anion acts as a bridge between the adjacent cationic gold(III) chelates. The structural 
parameters are summarised in Table 5.1.8. The Supramolecular structure is depicted in Figure 
5.1.7. 
 Table 5.1.8: Bond parameters for the C-H···F interactions (Å,˚) for RIZHAL. 
D—H···A D—H H···A D···A D—H···A 
C8—H8B···F2 0.969 2.559 3.138(9) 118.5 
C9—H9···F2 0.930 2.781 3.009(8) 95.0 




Figure 5.1.7: One dimensional network stabilised by C-H···F interactions in RIZHAL. 
RIZHEP and RIZHIT exhibit similar coordination geometries to that described above. The mean 
Au-Nimine and Au-Npyrrole bond lengths for these compounds measure 1.984 Å, 1.984 Å for RIZHEP 
and 2.028 and 1.976 for RIZHIT, respectively. Weak C-H···O interactions between the pyrrole 
ring CH hydrogen atoms and the oxygen atoms of the counter ion lead to a one-dimensional 
supramolecular structure co-linear with the b-axis. The anion acts as a bridge between the 
adjacent cationic gold(III) chelates. The structural parameters are summarised in Table 5.1.9 
The supramolecular structure is depicted in Figure 5.1.8. 
Table 5.1.9: Bond parameters for the C-H···O interactions (Å,˚) for RIZHEP. 
D—H···A D—H H···A D···A D—H···A 
C2—H2···O4 0.95 2.55 3.20(3) 126 






Figure 5.1.8: One dimensional network stabilised by C-H···O interactions in RIZHEP. 
RIZHIT shows π-stacking in the form of head-to-tail and oblique dimers as shown below in 
Figure 5.1.9.  The π-stacking is an indication of potential DNA intercalation. 
 
Figure 5.1.9: Head-to-tail π-stacked dimers of RIZHIT. 
The ligand H2L4 has been previously coordinated to a number of transition metals including 
Zn(II) in the compound BAQHEG. Compound BAQHEG crystallised in the orthorhombic space 
group Pnma with Z = 4. BAQHEG has a zinc(II) metal centre which is stabilised by four nitrogen 
donor atoms and has a distorted square-pyramidal coordination geometry with a water 
molecule occupying the fifth coordination site. The Zn(II) ion is displaced from the N4 plane as 
shown in Figure 5.1.10. In the presence of nitrogen donor atoms zinc favours square planar or 
square pyramidal coordination geometries. A two-dimensional network is stabilised by four 
unique hydrogen bonds in the solid state structure. The water and perchlorate molecules 
109 
 
bridges two metal chelates (A and B) in the lattice to form a dimer. The polymer expands along 
the c-axis as shown in Figure 5.1.11. The hydrogen bond parameters are summarised in Table 
5.1.10. 
Table 5.1.10: Hydrogen bond parameters (Å,˚) for BAQHEG. 
D—H···A D—H H···A D···A D—H···A 
C1—H1···O2 0.946(6) 2.502(9) 3.150(9) 125.7(4) 
N2—H5···O4 0.831(5) 2.13(1) 2.91(1) 155.6(5) 
O1W—H1W···O1 0.870 1.785 2.642 168.1 
O1W—H1W···O2W 1.066 1.687 2.752 179.6 
 
 
Figure 5.1.10: Out-of-plane distortion of the Zn(II) ion from the four-atom mean plane defined 




Figure 5.1.11: A two dimensional network is stabilised by four unique hydrogen bonds for 
BAQHEG. 
The ligand H2L4 has been previously coordinated to Mn(II) in the compound MAYQIM. 
Compound MAYQIM crystallised in the orthorhombic space group Pnma with Z = 4. MAYQIM 
has a manganese metal centre with is stabilised by four nitrogen donor atoms and two aqua 
ligands in the axial positons. MAYQIM has a distorted octahedral coordination geometry. The 
Mn(II) ion is located slightly above the N4 plane as shown in Figure 5.1.12. In the presence of 
nitrogen donor groups manganese prefers to form a six-coordinate species.  
 
Figure 5.1.12: Deviation of Mn(II) from planarity as defined by the coordinating nitrogen atoms 
for MAYQIM.   
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The same ligand has also been coordinated to Ni(II) in the compound MAYQOS. Compound 
MAYQOS crystallised in the orthorhombic space group Pnma with Z = 4. MAYQOS has a 
nickel(II) metal centre with is stabilised by four nitrogen donor atoms from the bis(imidazole-
imine) ligand and two aqua ligands found in the axial positons as shown in Figure 5.1.13. 
MAYQOS has a distorted octahedral coordination geometry. The Ni(II) ion is located slightly 
above the N4 plane. In the presence of nitrogen donor groups nickel has a preference for 
forming six-coordinate species.  
 
Figure 5.1.13: Crystal structure of MAYQOS showing the nominally octahedral coordination 
geometry. 
The ligand H2L4 also been coordinated to copper(II) in the compound MAYQUY. Compound 
MAYQUY crystallised in the monoclinic space group P21/n  with Z = 4. MAYQUY has a copper(II) 
metal centre which is stabilised by four nitrogen donor atoms in the equatorial position, one 
aqua ligands and one perchlorate oxygen atom in the axial positons shows a significant 
 Z-out distortion (elongated axial ligand bonds) as predicted by the Jahn-Teller theorem. This 
 Z-out distortion lowers the energy of all orbitals with a z-component and leads to an overall 
lower energy structure than could be achieved with an octahedral geometry.. The Cu(II) ion is in 




Figure 5.1.14: Deviation of Cu(II) from planarity as defined by coordinating nitrogen atoms for 
MAYQUY.   
A ligand similar to H2L8 has been coordinated to Cu(II) in the compound BAGHAT. Compound 
BAGHAT crystallised in the monoclinic space group P21/n with Z = 4. BAGHAT has a copper 
metal centre with is stabilised by four nitrogen donor atoms in the equatorial position and one 
perchlorate oxygen atom found in the axial positon, forming a distorted square-pyramidal 
coordination geometry. The Cu(II) ion is in the basal plane of the N4 donor atoms. The Cu(II) ion 
has a deviation of 0.143(2) Å from the defined N4 plane towards the apical position shown in 
Figure 5.1.15, this is a commonly observed distortion in square pyramidal copper(II) chelates. 





Figure 5.1.15: Deviation of Cu(II) from planarity as defined by the N4 donor atoms for BAGHAT.   
 
A ligand similar to H2L6 has been coordinated to Cu(II) in the compound KURQAR. Compound 
KURQAR crystallised in the monoclinic space group P21 with Z = 2. KURQAR has a copper(II) 
metal centre which is stabilised by four nitrogen donor atoms in the equatorial position and one 
aqua ligand in the axial positon. KURQAR has a distorted square-pyramidal coordination 
geometry as shown in Figure 5.1.16. The Cu(II) ion again shows an out-of-plane distortion 
towards the axial aqua ligand. A one-dimensional network is stabilised by hydrogen bonds in 
KURQAR. The NO3- ion bridges three molecules in the lattice to form a two-dimensional 
supramolecular structure which is co-planar with the ab plane. The bonding motif is complex, 







Figure 5.1.16: Deviation of Cu(II) from planarity as defined by the imidazole rings for KURQAR.   
 
Figure 5.1.17: Two-dimensional supramolecular structure of KURQAR viewed down the c-axis.  
The network illustrated in Figure 5.1.17 is supported by extensive hydrogen bonding. The 








Table 5.1.11: Hydrogen bond parameters stabilising the two-dimensional network of KURQAR. 
H-Bond D–H H∙∙∙A D∙∙∙A D–H∙∙∙A 
N6–H2∙∙∙O4 0.900 2.160 2.954(7) 146.7 
N2–H1∙∙∙O4 0.901 2.337 2.989(6) 129.2 
O1–H4∙∙∙O2 0.851 2.068 2.775(7) 140.1 
N6–H2∙∙∙O7 0.900 2.341 2.965(7) 126.4 
O1–H3∙∙∙O6 0.850 2.112 2.842(8) 143.9 
N2–H1∙∙∙O7 0.901 2.219 3.007(8) 145.7 
  
The bond lengths described in Table 5.1.11 are all significantly shorter than the sum of the van 
der Waals radii of the interacting atoms. Although bond length does not always correlate 
linearly with bond strength due to packing constraints in the lattice, these bonds are 
significantly shorter. This suggests that the interactions are likely to be moderate to strong.  
A ligand similar to H2L5 has been coordinated to Cu(II) in the compound GASQEW. Compound 
GASQEW crystallised in the triclinic space group P-1 with Z = 2. GASQEW has a copper(II) metal 
centre with is stabilised by four nitrogen donor atoms  in the basal plane and an axial chloro 
ligand. GASQEW exhibits a severely distorted square-pyramidal coordination as shown in 
Figure 5.1.18. The Cu(II) ion is displaced from the basal plane towards the apical chloro ligand 
as has been a trend in the copper(II) chelates studied thus far. The severe distortion of the 
coordination geometry is likely the result of the additional degrees of freedom allowed by the 
four-carbon di(azomethine) linkage as opposed to the three -carbon bridges previously studied. 
The NO3- molecules bridges two chelates (A and B) in the lattice to form a dimer, this could also 
be referred to as a hydrogen-bonded heterotetramer. The supramolecular structure is 







Table 5.1.12: Hydrogen bond parameters (Å,˚) for GASQEW. 
D—H···A D—H H···A D···A D—H···A 
N1—H4···O2 0.951 1.885 2.785(4) 157.0 
N6—H17···O2 0.950 1.900 2.827(4) 164.8 
 
 
Figure 5.1.18: Crystal structure of GASQEW illustrating a distorted square-pyramidal 
coordination. 
 
Figure 5.1.19: Metal chelates of GASQEW are bridged by hydrogen bonding through the nitrate 
counter ions and imidazole NH groups. This leads to a hydrogen-bonded heterotetramer. 
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An interesting feature of the above metal chelates coordinated to bis(imidazole-imine) ligands is 
that in all cases metal ion chelation has not required deprotonation of the imidazole NH. This is 
in stark contrast to the gold(III) chelates presented in this work which show concomitant 
deprotonation of the NH groups in all cases. This is consistent with the electron deficient 
gold(III) ion requiring the stronger sigma-donor ability of the anionic deprotonated imidazole 
NH for stability.  
5.1.3 Objectives  
 
The main aim of single crystal diffraction studies is to determine the solid state structure of the 
bis(imidazole-imine) ligands and their gold(III) chelates. The X-ray data will be used to deduce 
if these chelates can be effective DNA intercalators. 
5.2 Experimental 
 
All X-ray data were recorded on a Bunker Apex Duo diffractometer equipped with an Oxford 
Instruments Cryojet operating at 100(2) K and an Icoatec microsource operating at 30 W 
power. Ligand and chelate crystal refinement data are shown in Tables 4.2.1 and 4.2.2, 
respectively. All data were collected with Mo Kα (λ=0.71073 Å) radiation at a crystal-to-detector 
distance of 50 mm. All data collections were done using omega and phi scans with exposures 
taken at 30 W X-Ray power and 0.50˚ frame widths using APEX2[12]. The data were reduced 
with SAINT [12] using outlier rejection, scan speed scaling and standard Lorentz and 
polarisation correction factors. A SADABS semi-empirical multi-scan adsorption correction [12] 
was applied to all data. Direct methods, SHELXS [13] and WinGX [14] were used to solve the 
crystal structures. All non-hydrogen atoms were located in the difference density map and 
refined anisotropically with SHELXS [13]. The imidazole NH and water OH hydrogen atoms of 
the free ligands were located in the difference density map and refined isotropically. 
The gold(III) chelates have residual electron density in the E-map. These peaks were found near 
the gold(III) ion and are the result of strong absorption by the gold(III) ion which was 






Table 5.2.1: Crystal refinement data for ligands. 
Crystal Data H2L6 H2L7 
Chemical formula C16 H22 N6. 
1
2
 H2O C16 H22 N6. 
1
2
 H2O  
Molar mass (g.mol-1) 307.40 307.40  
Crystal system, space group 
 
Tetragonal, P 43 Tetragonal, P 41  
Temperature (K) 100 100  
a, b, c (Å) 9.6624 (13), 9.6624 
(13), 35.901 (5) 
9.6384 (6), 9.6384 
(6), 35.866 (2) 
 
α, β, γ (˚) 90, 90, 90 90, 90, 90  
V (Å3) 3351.8 (8) 3331.9 (4)  








Crystal size (mm) 0.50 × 0.19 × 0.12 0.35 × 0.20 × 0.15  
    
Data collection    
Diffractometer  Bruker APEXII CCD Diffractometer  
Absorption correction Multi-scanSADABS, Bunker2012 
No. of measured, independent and  
observed [I>2σ(I)] reflections 
14768, 3334, 3214  15571, 3447, 3337   
Rint 0.049 0.030  
(sin θ/λ)max (Å−1) 0.617 0.626  
    
Refinement     
R[F2> 2σ(F2)], wR(F2), S 0.056, 0.129, 1.20 0.042, 0.094, 1.19  
No. of reflections 3334 3447  
No. of parameters 434 434  
No. of restrains 1 1  
H-atom treatment H atoms treated by 




















Table 5.2.2: Crystal refinement data for chelates. 
Crystal Data [Au(L1)](PF6) [Au(L2)](PF6) [Au(L4)](Cl) 
Chemical formula C13H16AuF6N6P C15H20AuF6N6P C13H11AuCl0N6O  
Molar mass (g.mol-1) 598.25 626.31 499.70  
Crystal system, space 
group 
 
Monoclinic, C c Monoclinic, P21/c Monoclinic, C2/c  
Temperature (K) 100 100 100  






10.9751 (7), 16.4315 (10), 
9.4081 (6) 
 
α, β, γ (˚) 90, 107.011 (3), 
90 
90, 90, 90 90,117.171 (2),90  
V (Å3) 1732.3 (2) 1903.9 (2) 1509.40 (17)  










Crystal size (mm) 0.45 × 0.11 × 
0.03 
- -  
     
Data collection     
Diffractometer Bruker APEXII CCD Diffractometer 
Multi-scanSADABS, Bunker2012 Absorption 
correction 
No. of measured, 
independent and  
observed [I>2σ(I)] 
reflections 
9540, 4263, 4133  17044, 3560, 
3241  
7552, 2000, 1867   
Rint 0.026 0.033 0.021  
(sin θ/λ)max (Å−1) 0.706 0.618 0.682  
     
Refinement      
R[F2> 2σ(F2)], 
wR(F2), S 
0.018, 0.041, 0.87 0.043, 0.113, 1.08 0.023, 0.057, 1.07  
No. of reflections 4263 3560 2000  
No. of parameters 246 267 112  
No. of restrains 2 24 -  
H-atom treatment H atoms treated 







H-atom parameters constrained  






5.3 X-Ray Crystallography of Ligands 
5.3.1 X-Ray structural analysis of H2L6 
 
Ligand H2L6 crystallised in the tetragonal space group P43 as a monohydrate with the 
asymmetric unit containing two ligand molecules (Z = 8) and a single water molecule. A single 
molecule of the asymmetric unit is shown below in Figure 5.3.1. Key bond lengths and bond 
angles are summarised in Table 5.3.1. The two independent structures in the asymmetric unit 
are very similar, as indicated by the least square fit, which gives a root mean square deviation 
(RMSD) of 0.0804 Å.  
 
Figure 5.3.1: Thermal ellipsoid plot of H2L6, shown at 50% probability level. All hydrogen atoms 









Table 5.3.1: Key bond lengths and bond angles for H2L6. 
Bond Length(Å) Bond Angle(˚) 
N1-C1 1.329(6) N1-C1-N2 111.9(4) 
N1-C4 1.396(6) N1-C4-C5 121.3(4) 
N2-C1 1.349(6) N2-C2-C4 105.9(4) 
N2-C2 1.379(6) C4-N1-C1 104.6(4) 
C4-C5 1.471(7) N3-C5-C4 121.6(4) 
C2-C4 1.360(7) C1-N2-C2 107.4(4) 
N3-C5 1.269(6) C6-N3-C5 118.4(4) 
N3-C6 1.470(6)   
 
The N3-C5 bond length (1.269(6)˚) coupled with the N3-C5-C4 bond angle which measures 
121.6(4)˚ highlight the sp2 hybridised nature of the imine nitrogen atom and illustrates the 
double bond character of the imine bond.  
Comparing bond lengths, bond angles and torsion of H2L6 with similar bonds found in 
previously reported ligands such as EFAROU, NANTUS and XUVQAG clearly shows good 
correlation.  
The two ligand molecules in the asymmetric unit are similar in structure as illustrated by an 
RMSD = 0.0.791 Å. The key difference between the two molecules is the rotation of the 
imidazole-imine moieties relative to the six atom mean plane defined by the cyclohexyl rings. 
The angles between the 6-atom mean plane defined by the cyclohexyl ring and the two 8-atom 
mean planes defined by the methylimidazole and imine moieties measure 72.27 ˚ and 80.58 ° 
(mean  = 76.42°). The equivalent angles for molecule B measure 71.51 and 84.25 ° (mean = 
77.88 °).  
The ligand H2L6 exhibits a complex hydrogen bonded-network that stabilises a three-
dimensional supramolecular structure. The three-dimensional network is stabilised by eight 
unique hydrogen bonds. The water molecule bridges two molecules (A and B) in the lattice to 
form a dimer. The water molecule acts as the hydrogen bond donor and the imine nitrogen 
atoms of molecules A and B as the hydrogen bond acceptors. This dimer is then further 
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stabilised by a hydrogen bond between the imidazole NH (H-bond donor) of molecule A and the 
imidazole N atom (H-bond acceptor) of molecule B as shown in Figure 5.3.2 below. 
The hydrogen bond lengths and angles have been measured and reported below in Table 5.3.2. 
 
Figure 5.3.2: Solid state structure of H2L6 illustrating the hydrogen-bonded dimer bridged by a 
water molecule. The dimers are linked by additional hydrogen bonding to form a three-
dimensional supramolecular structure.   
Table 5.3.2: Hydrogen bond lengths (Å) and bond angles (˚) of H2L6. 
D-H···A D-H H···A D···A D-H···A 
O1W-H1W···N3 0.96(9) 2.04(8) 2.945(6) 155(7) 
O1W-H1W···N9A 0.87(9) 2.11(9) 2.941(6) 160(9) 
N7A-H7A···N1 0.84(5) 2.08(5) 2.921(6) 175(5) 
N2-H2···N8A 0.96(7) 2.25(7) 2.854(6) 120(5) 
N6-H6···N11A 0.98(7) 1.92(7) 2.891(5) 168(6) 
N5···H12-N12A 0.83(5) 2.04(5) 2.855(5) 171(5) 
 
In addition to bridging dimers within a column, the bridging ligand molecules cross-link the one 
dimensional columns of dimers leading to a two-dimensional hydrogen-bonded sheet. A single 
imidazole ring of the bridging molecule crosslinks dimers within the same column, stabilising 
the one-dimensional structure. The imidazole NH hydrogen bonds to the imidazole N atom of a 
single molecule in the dimer. The N-atom of the same bridging imidazole ring acts as an H-bond 
acceptor for the imidazole NH of an adjacent dimer. The second imidazole ring of the bridging 
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unit is H-bonded through the imidazole NH to the imidazole N atom of adjacent column. This 
stabilises the two-dimensional sheet. 
 
Figure 5.3.3: Cross-linking of adjacent dimers through hydrogen bonding between the imidazole 
NH and imidazole N atoms. The dimers (as illustrated in Figure 5.3.2) are shown in yellow. 
The combination of the extended hydrogen bonding in H2L6 in combination with the four fold 
symmetry of the tetragonal crystal system leads to very interesting columnar supramolecular 
structure. These columnar structures are highly cross-linked by intermolecular interactions. 
The structures are shown in Figure 5.3.4. 
 
Figure 5.3.4: Cross-linked columnar structure of H2L6 the result of a combination of hydrogen 
bonding and four-fold lattice symmetry. The structure is viewed down the c-axis. 
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The water molecules are found in the centre of the hydrogn-bonded columns and form 
hydrogen bonds with surrrounding molecules. The anti-configuration is needed for formation of 
the polymers. There hydrogen bonds from N1a to N2c extend the polymer down the c-axis and 
also form the circular shapes. The three dimensional polymer is a result of a repeating one 























5.3.2 X-Ray structural analysis of H2L7 
 
Ligand H2L7 crystallised in the tetragonal space group P41 with the asymmetric unit containing 
two independent molecules (Z = 8). The two independent ligand molecules in the asymmetric 
unit are similar in geometry as indicated by an RMSD of 0.2128 Å. A single molecule from the 
asymmetric unit is shown below in Figure 5.3.5. 
 
Figure 5.3.5: A thermal displacement plot of H2L7 shown at 50% probability level. All hydrogen 
atoms are represented as spheres of arbitrary radius. 
Bond lengths and bond angles describing the imidazole ring and imine moieties are summarised 
in Table 5.3.3. It is interesting to note that in both H2L6 and H2L7 the geometry about the imine 
bond is exclusively trans. This is ubiquitous in bis(pyrridyl-imine) and bis(pyrrolide-imine) 
Schiff base chelates. The cis configuration would lead to a greater level of non-bonded repulsion 








Table 5.3.3: Bond lengths and bond angles describing the imidazole ring and imine moieties of 
H2L7. 
Bond Length (Å) Bond Angle (˚) 
N1-C1 1.319(4) N1-C1-N2 112.7(3) 
N1-C4 1.391(4) N1-C4-C5 125.8(3) 
N2-C1 1.352(4) N2-C2-C4 105.9(3) 
N2-C2 1.367(4) C4-N1-C1 104.5(3) 
C4-C5 1.458(4) N3-C5-C4 125.5(3) 
C2-C4 1.378(4) C1-N2-C2 107.1(3) 
N3-C5 1.271(4) C6-N3-C5 115.4(2) 
N3-C6 1.469(4)   
 
The data in the above table clearly shows that the imine bond is once again significantly shorter 
than the remaining bonds. This is indicative of the double bond character. 
When comparing bond lengths of H2L7 with similar bond lengths, bond angles and torsion 
angles in the related compounds EFAROU, NANTUS and XUVQAG and XUVQAG it is noted that 
there is a particularly good correlation with NANTUS.  
The two ligand molecules in the asymmetric unit are similar in structure as illustrated by a root-
mean-square deviation (least squares fit) of the two molecules, RMSD = 0.1103 Å. The key 
difference between the two molecules is the rotation of the imidazole-imine moieties relative to 
the six atom mean plane defined by the cyclohexyl rings. The angles between the 6-atom mean 
plane defined by the cyclohexyl ring and the two 8-atom mean planes defined by the 
methylimidazole and imine atoms measure 72.27 and 80.58 ° (mean  = 76.42°). The equivalent 
angles for molecule B measure 71.51 and 84.25 ° (mean = 77.88 °).  
The ligand H2L7 exhibits a complex hydrogen-bonded network that stabilises a three-
dimensional supramolecular structure. The three-dimensional network is stabilised by five 
unique hydrogen bonds. The water molecule bridges two molecules (A and B) in the lattice to 
form a dimer. The water molecule acts as the hydrogen bond donor and the imine nitrogen 
atoms of molecules A and B as the hydrogen bond acceptors. This dimer is then further 
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stabilised by a hydrogen bond between the imidazole NH (H-bond donor) of molecule A and the 
imidazole N atom (H-bond acceptor) of molecule B as shown in Figure 1 below. 
The hydrogen bond lengths and angles have been measured and reported below in Table 5.3.3 
and the resulting supramolecular structure illustrated in Figure 5.3.6. 
 
Figure 5.3.6: Solid state structure of H2L7 displaying dimeric structure stabilised by hydrogen 
bonds. 
Table 5.3.4: Hydrogen bond lengths (Å) and bond angles (˚) of H2L7. 
D-H···A D-H H···A D···A D-H···A 
O1W-H1W···N6 0.80(5) 2.16(5) 2.929(4) 163(5) 
O1W-
H1W···N12A 
0.90(6) 2.11(6) 2.939(4) 153(3) 
N8-H8···N1 0.86(4) 2.05(4) 2.885(4) 162(4) 
N9-H9···N3 0.91(4) 2.16(4) 2.858(4) 132(4) 
N2-H2···N7 0.83(3) 2.03(3) 2.851(4) 171(3) 





Figure 5.3.7: Cross-linking of adjacent dimers through hydrogen between the imidazole NH and 
imidazole N atoms. The dimers (as illustrated in Figure 5.3.6) are shown in yellow. This hydrogn 
bonding motif leads to one dimensional columns. 
In addition to bridging dimers within a column, the bridging ligand molecule cross-links the one 
dimensional columns of dimers leading to a two-dimensional hydrogen-bonded sheet. A single 
imidazole ring of the bridging molecule crosslinks dimers within the same column, stabilising 
the one-dimensional structure. The imidazole NH hydrogen bonds to the imidazole N atom of a 
single molecule in the dimer. The N-atom of the same bridging imidazole ring acts as an H-bond 
acceptor for the imidazole NH of an adjacent dimer. The second imidazole ring of the bridging 
unit is H-bonded through the imidazole NH to the imidazole N atom of and adjacent column. 
This stabilises the two-dimensional sheet. 
As with H2L6, the combination of four-fold lattice symmetry associated with the tetragonal 
crystal system in conjunction with the extended hydrogen bonding leads to a highly 





Figure 5.3.8: Columnar structure of H2L7 viewed down the c-axis. The structure is stabilised by 
extensive hydrogen bonding. 
The water molecules are found in the centre of the columns (Figure 5.3.8) and form hydrogen 
bonds with surrrounding molecules. The anti-configuration is needed for formation of the 
polymers. The hydrogen bonds from N1a to N2c extend the polymer down the c axis and also 
form the columnar structures. The three dimensional polymer is a result of a repeating  









5.4 X-Ray Crystallography of Complexes 
5.4.1 X-Ray structural analysis of [Au(L1)][PF6] 
 
Ligand [Au(L1)][PF6] crystallised in the monoclinic, Cc space group with the asymmetric unit 
containing one molecule (Z=4). The single molecule in the asymmetric unit is seen below in 
Figure 5.4.1.  
 
Figure 5.4.1: A labelled thermal displacement plot of [Au(L1)][PF6], shown at 50% probability 
level. All hydrogen atoms are represented as spheres of arbitrary radius. 
Chelate [Au(L1)][PF6] exhibits a square planar coordination geometry, coordinated by the four 
nitrogen atoms, two imine nitrogen atoms and two imidazole nitrogen  atoms. Metal ion 
chelation has occurred with concomitant deprotonation of the imidazole NH groups yielding a 
dianionic ligand and monocationic chelate isolated as the hexafluorophosphate(V) salt. This is 
an interesting result as all previous examples of related ligands coordinated to divalent 3d 
transition metals show metal chelation without NH deprotonation. This illustrates the electron 
deficient nature of the gold(III) ion and the necessity of strong anionic sigma-donor atoms to 
stabilise the metal centre.  




Table 5.4.1: Bond lengths and bond angles describing the coordination sphere of [Au(L1)][PF6]. 
Bond Length(Å) Bond Angle (˚) 
N2-Au 2.005(3) N2-Au-N3 80.6(1) 
N3-Au 2.013(3) N2-Au-N6 103.0(1) 
N4-Au 2.022(3) N4-Au-N3 95.7(1) 
N6-Au 1.995(4) N4-Au-N6 80.7(1) 
 
The average Au-Nimine (N3 and N4) bond length measures 2.0175(4) Å which is consistent with 
the imine bond lengths reported in RIZHAL, RIZHEP and RIZHIT. The average Au-Nimidazole (N2 
and N6) bond length measures 2.000 (4) Å which is consistent with the imine bond lengths 
reported in RIZHAL, RIZHEP and RIZHIT.  The shorter bond length reported for the latter could 
be attributed to a stronger interaction between the gold(III) ion and the negatively charged 
imidazole N atom. The mean Nimine-Au-Nimine, mean Nimine-Au-Nimidazole and Nimidazole-Au-Nimidazole 
bond angels measure 95.7(1)°, 80.65(1)° and 103.0(1)°, respectively. These bond angles have an 
excellent correlation with the bond angles reported in RIZHAL, RIZHEP and RIZHIT. The 
bridging unit shows the characteristic out-of-plane distortion required to accommodate the sp3 
hybridised carbon atoms. The variation in the bond angles describing the coordination sphere is 
due to the differing bite of the tetradentate ligand. The bond angle associated with the five-
membered chelate rings is more acute than that of the six-membered ring. The Nimidazole-Au-
Nimidazole bond angle is the most obtuse as the imidazole rings are free to move apart, which 
would reduce no-bonded repulsion between the imidazole CH atoms.  
The solid state structure of [Au(L1)][PF6] also exhibits interactions between the electron 
deficient gold(III) ion and the imidazole N-atom of an adjacent molecule as shown in  
Figure 5.4.2. This interaction would serve to further stabilise the gold(III) ion in its high 
oxidation state. The distance of this interaction is 2.811(3) Å between the imidazole ring 
nitrogen atom and gold(III) ion of the adjacent complex. This interaction is significantly shorter 
than the sum of the van der Waals radii of the interacting atoms (by 0.399 Å) this suggests that 
the interaction is significant. This interaction is due to the electron deficient gold(III) ion which 
accepts electron density from adjacent aromatic systems which can be defined as Lewis 
acid/base interaction. Closely related Au-π interactions are known to stabilise DNA/chelate 




Figure 5.4.2: Au···N interactions of [Au(L1)](PF6) measuring 2.811(3) Å link adjacent molecules 

















5.3.2 X-Ray structural analysis of [Au(L2)][PF6] 
 
The complex [Au(L2)][PF6] crystallised in the monoclinic, P21/c space group with the 
asymmetric unit containing one molecule (Z=4). The single molecule in the asymmetric 
unit is shown below in Figure 5.4.3.  
 
Figure 5.4.3: A thermal ellipsoid plot of [Au(L2)][PF6]. It has been rendered at the 50% 
probability level. All hydrogen atoms are represented as spheres with indiscriminate radii. 
Chelate [Au(L2)][PF6] exhibits a square planar geometry and is chelated via the four nitrogen 
atoms, two imine nitrogen atoms and two imidazole nitrogen atoms. The bond lengths and bond 
angles describing the coordination sphere of the gold(III) ion with the nitrogen atoms are 




Table 5.4.2: Bond lengths and bond angles describing the coordination sphere of [Au(L2)][PF6]. 
Bond Length(Å) Bond Angle (˚) 
N2-Au 2.009(7) N2-Au-N3 80.5(3) 
N3-Au 2.019(7) N2-Au-N6 102.4(4) 
N4-Au 2.003(7) N4-Au-N3 95.5(3) 
N6-Au 1.966(7) N4-Au-N6 81.6(3) 
 
The average Au-Nimine (N3 and N4) bond length measures 2.000(10) Å which is consistent with 
the equivalent bond lengths reported in RIZHAL, RIZHEP and RIZHIT and [Au(L1)]PF6. The 
average Au-Nimidazole (N2 and N6) bond length measures 1.984(10) Å which is consistent with 
the imine bond lengths reported in RIZHAL, RIZHEP and RIZHIT.  The shorter bond length 
reported for the latter could be attributed to a stronger interaction between the gold(III) ion 
and the negatively charged imidazole N atom. The bond angles for Nimine-Au-Nimine, average 
Nimine-Au-Nimidazole and Nimidazole-Au-Nimidazole measures 95.5(3)°, 81.08(4)° and 102.4(4)°, 
respectively. These bond angles have an excellent correlation with the bond angles reported in 
RIZHAL, RIZHEP and RIZHIT and [Au(L1)]PF6. The bridging unit again shows the same out-of-
plane distortion, consistent with RIZHAL and RIZHEP. The structure shows an Au···π interaction 
between the gold(III) ion and the imidazole ring of an adjacent molecule.The distance of the 
Au···π interaction is 3.210(1). Interactions of this nature are common in gold(III) chelates and 
provide insight into why gold(III) complexes typically interact strongly with the highly aromatic 
DNA base pairs in vivo. 
 




5.3.3 X-Ray structural analysis of [Au(L4)][PF6] 
 
Ligand [Au(L4)][PF6] crystallised in the monoclinic, C2/c space group with the 
asymmetric unit containing half a molecule (Z=4). The single molecule is shown below 
in Figure 5.4.5. For clarity, only one C7 and hydroxyl group is shown. Bond lengths and 
bond angles describing the coordination sphere are shown in Table 5.4.3.  
 
Figure 5.3.5: A thermal ellipsoid plot of [Au(L4)]Cl shown at 50% probability level. All hydrogen 
atoms are represented as spheres with indiscriminate radius. 
Chelate [Au(L4)]Cl exhibits a square planar geometry and is chelated via the four nitrogen 
atoms, two imine nitrogen atoms and two imidazole nitrogen atoms. This geometry is consistent 
with other gold(III) chelates and is a result of the d8 electronic configuration and the associated 






Table 5.4.3: Bond lengths and angles for [Au(L4)][PF6]. 
Bond Length(Å) Bond Angle (˚) 
N2-Au 1.996(3) N2-Au-N3 80.86(17) 
N3-Au 2.003(4) N2-Au-N6 102.84(17) 
N4-Au 2.003(4) N4-Au-N3 95.49(3) 
N6-Au 1.996(3) N4-Au-N6 80.86(17) 
 
The average Au-Nimine (N3 and N4) bond length is 2.003(6) Å which is consistent with the 
equivalent bond lengths reported in RIZHAL, RIZHEP and RIZHIT. The average Au-Nimidazole (N2 
and N6) bond length measures 1.996(4) Å which is consistent with the equivalent bond lengths 
reported in RIZHAL, RIZHEP and RIZHIT.  The bond angles for Nimine-Au-Nimine , Nimine-Au-Nimidazole 
and Nimidazole-Au-Nimidazole measures 95.49(3)°, 80.86(24)° and 102.84(17)°, respectively. The 
variation in the bond angles is, as before, attributed to the varying bite of the ligand and the 
resulting five- and six- membered chelate rings. The free Nimidazol-Au-Nimidazole bond length is not 
resticted by the ligand structure and is therefore significantly more obtuse than the other bond 
angles.   
5.4 Conclusions  
 
Two ligands and three gold(III) chelates were studied by single crystal X-ray diffraction. The 
two ligands crystallised as the hemihydrate (i.e. a single water molecule associated with the two 
independent ligand molecules in the asymmetric unit. This allowed for hydrogen bonding. The 
D···A distances range from 2.921 to 2.945 Å and the D-H···A bond angles range from 155.27 to 
174.94˚. The hydrogen bonding allowed for formation of very interesting columnar structures.  
The three gold(III) chelates all had a square planar coordination geometry. Metalation required 
depronation of the imidazole NH resulting in a dianionic tetradentate N4-donor ligand and a 
cationic chelate. The imine nitrogen donor was found to have a longer bond to the gold(III) ion 
than the anionic imidazole nitrogen. The mean Au-Nimine and Au-Nimidazole bond lengths measure 
2.007 Å and 1.993 Å, respectively. Au···π interactions are present in two chelates which serves 
as an indication that potential chelate/DNA interactions are favourable.  
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Chapter 6| Computational Studies 
6.1.1 Introduction  
 
Wavefunctions can generally be used to generate data in electronic structure simulations. A 
wavefunction is a mathematical expression describing the probability of finding an electron in a 
certain location as the exact position cannot be precisely known [1]. Solving a wavefunction is 
only possible for single electron atoms such as hydrogen, an alternative method for more 
chemically relevant systems is therefore required. Density Functional Theory (DFT) is an 
indirect way of calculating the wavefunction of an atom or molecule. It relies on the ground 
state electronic function of a molecule which can be determined, the wavefunction can then be 
approximately solved based on the calculated electron distribution of a molecule [2,3]. Physical 
characteristics such as optimised geometries, vibrational frequencies, electronic transitions and 
NMR data can be calculated once the wavefunction is determined. 
DFT simulations require the application of both a basis set and density functional. The basis set 
is the set of atomic functions that describes the number and type of atomic orbitals used and the 
region in space to which the electron is restricted [2,3]. The larger the basis set, i.e. the fewer 
restrictions that are placed on an electrons, the more computationally expensive. However, 
larger basis sets tend to give more reliable results. The density functional used for all complexes 
is PBE1PBE [4,5] which is a gradient corrected functional, meaning it uses electron spin 
densities and their gradients [1]. A functional is a mathematical entity which produces an 
instruction from a set of coordinates or variables; it is in essence a function of a function. The 
basis set LanL2DZ (Los Alamos National Laboratory 2-double-zeta) was used for all complexes 
because it can be used for atoms in the range of H, Li-Ba, La-Bi. LanL2DZ makes use of effective 
core potentials. Since second and third row elements of the Periodic Table have very large 
numbers of electrons it can become computationally too demanding to explicitly include these 
electrons in the simulations. When an effective core potential is applied, it is assumed that the 
core electrons do not play a significant role in the bonding and physico-chemical properties of 
molecules and they are therefore replaced with a single electronic potential. The valence 
electrons are still included [1, 6, 7, 8, 9].  
Ligand calculations made use of B3LYP (Beck, 3-parameter, Lee-Yang-Parr) density functional. 
This method considers proton affinities, total energies and ionization potentials. The basis set 
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used for ligand calculations as 6-311G which applies to atoms from H to Kr and implicitly 
includes all electrons [10, 11].  
6.1.2 Previous computational studies on related 
compounds  
 
The following contains basic details of select molecular simulation studies on compounds 
related to the bis(imidazole-imine) compounds in this work. The survey was primarily used to 
gauge the most appropriate basis sets and functionals to apply in the present study. Previous 
DFT studies have been carried out on bidentate pyrrolide-imine compounds related to the 
bis(imidazole-imine) ligands synthesised in this study [19]. The previous studies were 
undertaken to determine the geometric optimisations, vibrational frequency and electronic 
transitions. The calculations were performed at the B3LYP/6-311G(d,p) level of theory [19]. 





Figure 6.1.1: The general structure of the pyrrolide-imine Schiff base ligands previously studied 
by DFT methods.  
The results of these molecular simulations were in excellent agreement with the experimental 
data and allowed for a deeper understanding of the experimental results. Of particular interest, 
the relative energies of the optimised structures and solid state structures were probed. This 
gave insight into the effects of the solid-state interactions on the geometries of the  
free ligands. The electronic spectra and the orbitals involved in the electronic transitions were 
also simulated. These data were accurately simulated and highlight the suitability of the chosen 
level of theory for the present study.  
The following contains basic details of previously reported molecular simulation studies on 
compounds related to the gold(III) chelates in this work. The survey was primarily used to 
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gauge the most appropriate basis sets and functionals to apply in the present study as well as to 
determine the diversity of previous studies. Previous DFT studies have been carried out on 
bidentate pyridylamido gold(III) chelates [20,21]. In general either the LanL2DZ basis set or the 
split basis set which applies LanL2DZ to the gold(III) ion and 6-311G to all other atoms are 
used[20,21]. Similar to the above, geometry optimisations were performed as well as electronic 













Figure 6.1.2.2: The structure of the pyridylamido gold(III) chelate previously studied by DFT 
methods. 
As well as the DFT studies mentioned above, previous work has also made use of molecular 
mechanics simulations to probe the interactions of gold(III) chelates with DNA. [21] This 
enabled Akerman et al. to determine base pair specificity for the binding site of the gold(III) 
chelate. Molecular mechanics is suited for this type of research as it is more computationally 
economical than DFT and allows for the stimulation of biomolecules such as DNA. This will be a 







6.2 Computational method  
 
All DFT calculations were performed with Gaussian 09W [22]. X-ray coordinates were used as 
input structures where possible and the input files were created using GuassView 5.0 [23]. For 
all calculations, there were no symmetry constraints imposed. All ligand simulations were 
performed at the B3LYP/6-311G(d,p) level of theory. For added accuracy single first 
polarization functions (d,p) were added. The basis set LanL2DZ (Los Alamos National 
Laboratory 2-double-zeta) and PBE1PBE was used for all complexes. For electronic transition 
energies the TD-DFT method was used [12, 13, 14, 15, 16, 17, 18]. 
6.3 Results and discussion  
 
6.3.1 Gold(III) chelates 
 
Geometry Optimisation Results  
The geometry-optimised structure i.e., the lowest energy structure was calculated for all 
gold(III) chelates using the PBE1PBE/LanL2DZ level of theory. The DFT-calculated structures 
were then compared to the experimentally determined X-ray structures where possible to 
determine accuracy of the molecular simulations. The calculations were conducted in the gas 
phase with no intermolecular interactions considered. The X-ray structure will have a slightly 
more distorted square planar geometry due to π-π interactions between adjacent molecules, the 
DFT calculated structure will not experience the same π-π interactions meaning there will be no 
distortions from the lowest energy geometry. A summary of the bond lengths and bond angles 
for the experimental and calculated structures is shown in Table 6.3.1. 
Figure 6.3.1 shows the is the least-squares fit for the calculated and experimentally X-ray 
structures of [Au(L1)]+, [Au(L2)]+ and [Au(L4)]+. The overlays of the structures are almost 
identical as indicated by the small value of the root-mean-square deviations (RMSDS) of 0.1518, 
0.0791 and 0.3149 Å, respectively. The blue structure represents the X-ray structure and the 





  [Au(L1)]+   [Au(L2)]+   [Au(L4)]+ 
 
Figure 6.3.1: Least-squares fit for the DFT calculated and X-ray structures for [Au(L1)]+, 
[Au(L2)]+ and [Au(L4)]+. The RMSDs are indicated for each molecule on the diagram (measured 
in Å). 
The low RMSDs indicated above show that the calculated structures are in good agreement to 
the experimental structures determined by single crystal X-ray diffraction. This suggests that 
the level of theory used is appropriate and that the calculated structures of [Au(L9)]+ and 
[Au(L10)]+ are likely to be accurate representations of  the experimental structures. The 
calculated structures of [Au(L9)]+ and [Au(L10)]+ are shown below in Figure 6.3.2. 
 
Figure 6.3.2: DFT calculated structures for [Au(L9)]+, [Au(L10)]+. 
The DFT-simulated structures in Figure 6.3.2 show the same square planar coordination 
geometry as exhibited by the experimental X-ray structures. The bridging unit also shows the 




Table 6.3.1: Summary of DFT-calculated and experimental bond lengths, bond angles and 
torsion angles of [Au(L1)]+, [Au(L2)]+ and [Au(L4)]+. 
 Structural Feature Calculated Experimental % Difference  
   
   
   
   









Bond Lengths/Å      
Au-Nimdazole 2.038 2.000 1.90  
Au-Nimine 2.070 2.018 2.60  
Bond Angles/ ˚     
Nimdazole-Au-Nimdazole 102.72 103.00 0.27  
Nimdazole-Au- Nimine 96.52 95.70 0.86  
Nimine-Au Nimine 80.37 80.70 0.41  
   
   
   
   
   








Bond Lengths/Å      
Au-Nimdazole 2.039 1.984 2.77  
Au-Nimine 2.068 2.000 3.40  
Bond Angles/ ˚     
Nimdazole-Au-Nimdazole 102.99 102.37 0.02  
Nimdazole-Au- Nimine 95.99 95.54 0.47  
Nimine-Au Nimine 80.49 81.59 1.35  
   
   
   
   









Bond Lengths/Å      
Au-Nimdazole 2.037 1.996 2.05  
Au-Nimine 2.067 2.003 3.20  
Bond Angles/ ˚     
Nimdazole-Au-Nimdazole 102.61 102.84 0.22  
Nimdazole-Au- Nimine 96.61 95.49 1.17  





 𝑥 100 
The calculated and experimental data show very good correlation. The percentage difference is 
relatively low with the highest being 3.40%. This suggests that the level of theory used is 
appropriate and the calculated data is reliable. In general, the bond angles of the coordination 
sphere are particularly well estimated. This is likely because the reduced degrees of freedom 





Vibrational Frequency Data 
The vibrational frequencies for the gold(III) complexes were calculated from the geometry 
optimized structures at the PBEPBE/LanL2DZ level of theory. It could be concluded that all 
structures were optimized to an energy minimum as no negative Eigen values were obtained. As 
a representative example, the experimental results obtained for complex [Au(L2)](PF6) will be 
compared to those simulated for [Au(L2)]+. The remaining chelates show a similar trend and 
have been omitted to avoid repetition.  The calculated IR plot is compared to the experimental 
IR plot for [Au(L2)]+ is shown below in figure 6.3.3.  
 
Figure 6.3.3: Overlay of the experimental and DFT-calculated frequency data of [Au(L2)][PF6] 
and [Au(L2)]+. The experimental data has been offset by 0.3 absorbance units. 
The overlay of the experimental and calculated IR spectra of [Au(L2)][PF6] clearly shows a good 
correlation of the data. The PBE1PBE/LanL2DZ level of theory estimated the vibrational 
frequencies well. The percentage difference calculated is less than 1.2% which further proves 
that the estimation of the I.R. spectrum is accurate. The most notable difference between the 
experimental and DFT-calculated spectra is it ca. 800 cm-1. This corresponds to the 









The slope of a plot of experimental versus calculated frequencies for [Au(L2)](PF6) provides a 
scaling factor which indicates that the experimental frequencies are smaller on average by a 
factor of 0.998 compared to the calculated data, Figure 6.3.4. 
 
Figure 6.3.4: Plot of vibrational frequencies of [Au(L2)][PF6] versus [Au(L2)]+.  
The scaling factor (slope of a plot of experimental versus calculated data) can be directly 
determined as the plot passes through the origin. The scaling factor shows that on average the 
experimental frequencies are smaller by a factor 0.998(7) than the calculated frequencies. 
There is a very good correlation between the experimental and calculated data. Table 6.3.2 is a 
summary of the data used in the scaling factor plot and shows the percentage difference 
between the values.  
 
Table 6.3.2: Summary of calculated and experimental frequencies for [Au(L2)]+. 
Vibrational mode  Experimental  Calculated Difference (%)* 
CH3 3127 3109 0.58 
C-H (imine) 923 934 1.19 
C-H (CH2CH2CH2) 3061 3089 0.91 
C-H (CH2CH2CH2) 2966 2965 0.03 
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NMR spectral Data 
The two NMR spectra, i.e. 1H and 13C were calculated using the GIAO method with the PBE1PBE 
hybrid functional coupled with the LANL2DZ basis set. The solvent model used was dimethyl 
sulfoxide for the calculation. A CPM solvent model was applied this method places the molecule 
in a field with a dielelectric constant equal to that of the solvent in question. This method is 
more computationally economical than implicitly including all solvent molecules surrounding 
the molecule. As a representative example, the experimental results obtained for complex 
[Au(L2)](PF6) will be compared to those simulated for [Au(L2)]+. The remaining chelates show a 
similar trend.  The calculated chemical shifts are in relatively poor agreement and were 
overestimated in all cases. Figure 6.3.5 shows the structure of [Au(L2)]+ and the atom labelling 





















Figure 6.3.5: Structure and atom labelling scheme of [Au(L2)]+. 










Table 6.3.3: Summary of the calculated and experimental 1H NMR chemical shifts of [Au(L2)]+. 
Proton  Calculated (ppm) Experimental 
(ppm) 
Difference (%)* 
2 2.8627 2.53 13.2 
6 4.3089 3.47 24.2 
1 8.3680 8.46 1.09 
5 8.8219 8.81 0.14 





 𝑥 100 
Table 6.3.4: Summary of the calculated ad experimental 13C NMR chemical shifts of [Au(L2)]+. 
Carbon Calculated (ppm) Experimental (ppm) Difference (%)* 
2 11.5052 13.93 17.4 
8 19.74595 14.68 34.5 
6 63.8702 61.62 3.7 
4 123.193 153.20 19.6 
1 139.948 134.66 3.9 
5 146.134 162.98 10.3 
3 150.209 147.97 1.5 





 𝑥 100 
The calculated and experimental data show a poor correlation. All peaks were overestimated
i.e., were estimated to be further downfield than was experimentally observed. The percentage 
difference is high in most cases. A plot of the experimental and calculated data to try and 
estimate a scaling factor did not yield a straight line, indicating a random error, which could not 
be easily accounted for. Interestingly, the simulations were more accurate for aromatic than 
alkyl protons (percentage errors <2%). This may be because the aromatic protons have fewer 
degrees of freedom and the static gas phase structure is therefore a more realistic 
representation of the experimental structure in solution. In contrast, the alkyl groups will be 
dynamic in solution during NMR data collection and could therefore be more difficult to 
accurately simulate.  
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Electronic Transition Results  
The electronic transitions for the gold(III) chelates were calculated using the level of theory 
described above, however, the TD-DFT method was used so as to calculate the excited states 
involved in electronic transitions. A dimethyl sulfoxide solvent continuum was used in the 
calculations to account for any solvent effects. As a representative example, the experimental 
results obtained for complex [Au(L2)](PF6) will be compared to those simulated for [Au(L2)]+. 
As shown experimentally, the structure of the di(azomethine) unit does not have a significant 
impact on the electronic spectra. The same was observed for the simulated data. The results are 
therefore comparable to that presented for [Au(L2)](PF6). To avoid repetition the bulk of the 
data will not be shown, but is available in the Appendix C. 
 
Figure 6.3.6: Superposition of the calculated and experimental UV/visible spectra for [Au(L2)]+. 
The calculated spectra have been scaled. 
 
Figure 6.3.6 shows a moderate to poor correlation between the two spectra. The extinction 
coefficient hasn’t been correctly calculated. The intensities of the transitions have been 
underestimated. The calculated spectra also show a blue shift relative to the calculated spectra. 
The most significant difference in the data lies in the position of the LMCT band. This is 































predicted to be a significant band at approximately 430 nm in the DFT-simulated spectrum. In 
the experimental spectrum it is less intense and significantly blue-shifted. 
The orbitals involved in key transitions are shown below in Figure 6.3.6. The remaining 
UV/visible superposition data can be found in Appendix C.  
   
  HOMO: 85     LUMO: 86 
   
  HOMO-1: 84     LUMO+1: 87 
   
  HOMO-2: 83     LUMO+2: 88 
Figure 6.3.7: The electronic orbitals of [Au(L2)]+ involved in the most significant transitions. 
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In Figure 6.3.7 it is noted that the HOMO orbital is of π-symmetry with the orbital residing over 
the imidazole rings and imine bonds. The dxy orbitals of the gold(III) ion is also evident in the 
HOMO plot. The LUMO is seen to have a σ-symmetry with the dx2-y2 orbitals of the gold(III) 
mixing with the σ orbitals of the ligand. The orbitals involving most transitions are summarized 
in Table 6.3.1.5 below. 





Molecular Orbitals Type Oscillator  
Strength  
261 309 82  86; 81  87; 84  87 π  σ*, π  π*, π  π* 0.2883 
 315 78  86; 80  87; 85  87 π  σ*, π  π*, π  π* 0.2059 
342 422 83  86; 85  87 π  σ*, π  π* 0.1322 
 453 83  86; 85  87 π  σ*, π  π* 0.0432 
 
The relatively poor correlation between the experimental and calculated spectra is attributed to 
the level of theory used in the calculations; PBE1PBE/LanL2DZ. This basis set makes use of 
effective core potentials and only makes use of valence electrons in the calculations, which may 
compromise the reliability of the results. In comparison the ligand spectra were estimated 
significantly more accurately, this is due to the application of the larger 6-311G(dp) basis set. 
The results for the metal chelate simulations may therefore potentially be improved by the use 
of a split basis set, applying the LanL2DZ basis set to the metal ion only and the larger, more 












6.3.2 Ligands  
 
Geometry Optimisation Results  
The geometry-optimised structure was calculated for the ligands using PBE1PBE/6-311G(d,p) 
level of theory. The DFT-calculated structures were then compared to the experimental X-ray 
structures for two ligands to determine the accuracy of the selected method. The calculations 
were conducted in vacuo, therefore no intermolecular interactions were considered. A summary 
of the comparisons of bond lengths and bond angles is shown in Table 6.3.6. Shown in Figure 
6.3.8 is the least-squares fit for the DFT-simulated and X-ray structures of H2L6 and H2L7. The 
two structures are almost indistinguishable an RMSD of 0.0791 Å.  
 
                                                    
(a) H2L6(0.0791 Å)          (b) H2L7(0.0791 Å) 
 
Figure 6.3.8: Least-squares fit for the DFT calculated and X-ray structures for (a) H2L6 and  









Table 6.3.6: Summary of the DFT-calculated and experimental bond lengths, angles and torsion 
angles of H2L6 and H2L7. 
Ligand Torsion angel* (˚) % diff. C=N-C angel (˚) % diff.e C=N length (Å) % diff. 
 Calc Exp  Calc Exp  Calc Exp  
H2L6 177.3(5) 179.4 1.2 121.6(4) 120.9 0.6 1.269(6) 1.277 0.6 
H2L7 179.9(3) 179.9 0.0 125.5(3) 123.8 1.4 1.271(4) 1.277 0.5 
* Torsion angle between imidazole ring and aromatic moiety  
The calculated and experimental data show excellent correlation which suggests that the level 
of theory used is appropriate and the calculated data is reliable. An interesting point is that 
although the geometry of the molecules were simulated as monomers in the gas phase, there is 
still excellent agreement with the experimental geometrical conformation. This suggests that 
although the solid-state structure is involved in extensive hydrogen bonding, the molecule has 
had to undergo very minimal deviation from the lowest energy conformation to allow for 
optimal hydrogen bonding. This would suggest that the solid state structure with its low energy 
molecular conformation coupled with the stabilising effects of the hydrogen bonding would 
















Vibrational Frequency Data 
The vibrational frequencies were calculated for comparison with the experimental IR data as 
well as to confirm the optimised structure was the lowest energy conformation on the global 
potential energy surface. As a representative example, the experimental results obtained for 
ligand H2L6 will be compared to those simulated for H2L6. The remaining ligands show a similar 
trend and have been omitted to avoid repetition. The calculated IR plot is compared to the 
experimental IR plot below in Figure 6.3.9 The slope of the plot, of the calculated versus the 
experimental IR stretching and bending frequencies Figure 6.3.10, would give a scaling factor 
and will remove systematic errors in the calculated values. 
 
 
Figure 6.3.9: Overlay of the experimental and calculated IR spectrum of H2L6. 
The overlay of the experimental and calculated IR spectrum of H2L6 shows a moderate 
correlation of the two spectra. The B3LYP/6-311G level of theory overestimated the vibrational 
frequencies to a small extent. This is indicated by the plot of experimental versus calculated 






































Correlation coefficient = 0,999
Slope = 0,962(0)
 
Figure 6.3.10: Plot of calculated versus experimental frequencies for H2L6. 
The plot in Figure 6.3.10 gives a scaling factor which could be applied to the simulated data to 
increase the accuracy. Notably, the correlation for the free ligand is slightly less convincing than 
that of the gold(III) chelates. This is unexpected since the former makes use of a larger basis set 
in the simulations which implicitly includes all electrons in the calculation. The likely reasons 
for the deviation is that the solid state structure is heavily involved in hydrogen bonding, which 
can influence the stretching frequency by altering the position of electrons in the molecule and 
therefore bond order. If these effects were included in the simulations then it is likely that the 










NMR spectral data 
The two NMR spectra, 1H and 13C were calculated using the GIAO method with the B3LYP hybrid 
density functional and the 6-311G(dp) basis set. The solvent model used was methanol for the 
NMR simulation. The calculated 1H NMR chemical shifts are in poor agreement with the 
experimental data in all cases. The comparison between the calculated and experimental 
chemical shifts is summarised in Table 6.3.7. Table 6.3.8 summarises the equivalent data for the 
13C NMR spectra. . Figure 6.3.11 shows the structure of H2L6 and the atom labelling scheme used 


















Figure 6.3.11: Structure and atom numbering scheme used for H2L6.  
 
Table 6.3.7: Summary of the DFT-calculated and experimental chemical shifts of the 1H NMR 
spectrum for H2L6. 
Proton  Calculated (ppm) Experimental 
(ppm) 
Difference (%)* 
2 2.85 2.29 24.5 
6 3.86 3.21 20.2 
1 8.04 7.44 8.1 
5 8.96 8.06 11.2 




Table 6.3.8: Summary of the DFT-calculated and experimental chemical shifts for the 13C NMR 
spectra of H2L6. 
Carbon Calculated (ppm) Experimental (ppm) Difference (%)* 
2 10.20 11.88 14.1 
7 36.09 33.57 7.5 
6 79.35 74.20 6.9 
4 133.69 141.62 5.6 
1 137.97 125.96 8.7 
5 153.52 150.09 2.3 
3 142.24 136.67 4.1 





 𝑥 100 
The calculated and experimental data has a moderate correlation, significantly more 
satisfactory than that for the 1H NMR data. All peaks were overestimated as was the case with 
the gold(III) chelates. The percentage difference is relatively high with the highest being 14.1%. 
No scaling factor could be determined to increase the accuracy for results as the error seemed 














Electronic Transition Results  
The superposition of the DFT-calculated and experimental UV/visible spectra for H2L6 shows an 
accurate correlation, with only a slight blue shift in the simulated data. The orbitals involving 
the key transitions are shown below in Figure 6.3.13. The remaining UV/visible superposition 
data is available in Appendix C. 
 
Figure 6.3.12: Superposition of DFT-calculated and experimental UV/visible spectra for H2L6. 







































    
  HOMO: 80     LUMO: 81 
                            
HOMO-1: 79     LUMO+1: 82 
                 
  HOMO-2: 78     LUMO+2: 83 
Figure 6.3.13: Figure 6.3.13 shows that all the molecular orbitals involved in the transitions of 












Molecular Orbitals Type Oscillator  
Strength  
260 196 72  81; 75  81;76 82 π  π *, π  π*, π  π* 0..1347 
 242 77  81; 78  81; 78  82 π  π *, π  π*, π  π* 0.5616 
 254 79  81; 79  82; 8081 π  π *, π  π*, π  π* 0.2377 
 
6.4 Conclusion  
 
Density functional theory simulations were performed for the free ligands H2L6 and H2L7, as 
well as the gold(III) chelates. The resulting simulations were compared to the experimental data 
to determine the accuracy of the simulations and to deconvolute the experimental data. 
The least-squares fits of the experimental (X-ray) and DFT-simulated data were in good 
agreement for both the free ligands and gold(III) chelates. This suggests the the level of theory 
used for the simulations (B3LYP/6-311G(d,p)) and PBE1PBE/LanL2DZ, respectively) were 
appropriate.  
The vibrational frequency data correlated very well with the experimental data. There was a 
slight overestimation of vibrational frequencies for the ligands whereas the vibrational data for 
the chelates were excellent agreement with the experimental data. The difference is attributed 
to to the extensive hydrogen bonding of the free ligands in the solid state.  
1H and 13C NMR calculations were performed for all ligands and chelates. The simulations had 
poor to moderate results. Some peaks had moderate percentage differences while others were 
overestimated. No scaling factor could be determined to increase the accuracy of the results.
In general, the aromatic protons were estimated more accurately than the alkyl protons.  
The electronic transition data for the chelates were relatively poor, particularly for the 
prediction of the position of the LMCT bans. The electronic transition data for the ligands had a 
good correlation with a very slight blue shift in the simulated data. 
The overall results for the DFT simulations were generally fairly accurate. The ligand 
calculations were more accurate than the chelate simulations which is expected as the basis set 
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Chapter 7| Conclusions and Future Work 
7.1 Conclusion  
 
Seven novel bis(imidazole-imine) Schiff base ligands were successfully synthesized. The ligands 
consist two methyl-imidazole rings joined via a di(azomethine) bridging unit. The ligands 
differed by the structure of the di(azomethine) linkage except for H2L3 which differs by the 
absence of a methyl group on the imidazole ring. The ligands were designed to chelate gold(III) 
via strong σ-donor nitrogen atoms. For metal ion chelation, deprotonation of the imidazole NH 
is required. This yields a tetradentate, dianionic ligand. Chelation of the tetradentate N-donor 
ligands results in cationic gold(III) chelates with a square planar coordination geometry. These 
were isolated as either the hexafluorophosphate(V) or chloride complex salts. The source of the 
gold(III) ion was [Bu4N][AuCl4] with a two-fold excess of ligand used in the chelation reactions. 
This metal salt was chosen as it does not hinder the deprotonation of the ligands; as required 




















































































Using various spectroscopic techniques such as NMR (1H, 13C, cosy, hsqc, 19F and 31P), FTIR and  
UV-visible spectroscopy as well as mass spectrometry, all ligands and metal chelates were fully 
characterized. Both the 1H, 13C NMR showed a downfield shift of the peaks when comparing the 
free ligands to the respective chelates. This was due to the deshielding effect of the gold(III) ion 
and confirmed metal ion chelation. UV-visible spectroscopy showed one band for the free ligand 
which was π-π* transition and two bands for the gold(III) chelate which were assigned as π-π* 
transition at higher energy and an LMCT band at longer wavelengths. 
X-Ray crystallography was used to determine the solid state structures of two ligands and three 
gold(III) chelates. The ligands crystallized as the hemihydrate with one water molecule 
associated with the two interdependent ligand molecules in the asymmetric unit. The ligands 
were found to form stable hydrogen-bonded networks with the water molecule. The water 
molecules are found in the centre of hydrogn-bonded columns forming hydrogen bonds with 
the surrounding ligand molecules. The anti-configuration of the ligands is required for 
formation of the polymers. The hydrogen -bonded columns are co-linear with the c-axis. The 
three-dimensional structure is a result of a cross-linking the columns through additional 
hydrogen bonds. 
X-ray diffraction data showed the gold(III) chelates all had a square planar coordination 
geometry. This geometry is ubiquitous for d8 metal ions with the associated vacant dx2-y2 
orbitals. The deprotonation of the imidazole NH groups resulted in a dianionic tetradentate N-
donor ligand. The average Nimine bond length measures 2.007 Å and the average Nimidazole bond 
length measures 1.993 Å. The gold(III) chelates, square planar geometry deviated slightly from 
the ideal square planar geometry with an acute bond angle of 80.73˚ (Nimine-Au-Nimidazole). This 
bond angle is constrained by the bite angle of the free ligands and associated five-membered 
chelate ring. 
Density Functional Theory (DFT) was used to determine various properties of the ligands and 
gold(III) chelates. The DFT-calculated data were compared to the experimental data to 
determine the efficiency of the chosen basis set and hybrid functional applied. DFT was also 
used to gain a deeper understanding of the experimental data. The level of theory used for 
ligands was  
B3LYP/6-311G (d,p) and for the gold(III) chelates PBE1PBE/LanL2DZ. DFT was used to 
calculate the optimized geometry, NMR and electronic spectra. The vibrational frequencies for 
both ligands and chelates showed no negative Eigen values which implies that the optimized 
geometry is indeed the true minimum on the global potential energy surface. 
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The geometry-optimized structures had a very good correlation with the X-ray structures. The 
percentage difference in bond lengths for Au-Nimine is 3.25% and for Au-Nimidazole is 3.71%. The 
percentage difference in bond angles for Nimdazole-Au-Nimdazole, Nimdazole-Au- Nimine and Nimine-Au-
Nimine were 0.02, 0.47 and 1.35%, respectively.  
The electronic spectra showed reasonable correlation with experimental data, particularly in 
the case of the ligands, but the NMR spectra were poorly calculated in some cases. There was in 
general good correlation between the calculated properties and experimental data, suggesting 
the level of theory used was appropriate.  
The chelates were designed to exploit the square planar nature of the gold(III) ion to produce 
metal aromatic metal chelates suitable for DNA intercalation to control the proliferation of 
tumour cells. Both direct DNA binding titrations and competitive DNA binding studies did not 
show any significant affinity towards DNA. The likely reason for this is that the methyl groups 
on the imidazole rings, which are required to stabilise the metal ion through their inductive 
effect, prevent the intercalation process. This class of compounds therefore needs further 
development to achieve the final goal of chemotherapeutic agent. The future avenues of 
research are described below.  
7.2 Future Work 
 
The main aim of this study was to synthesize and fully characterize a range of seven novel 
imidazole-imine Schiff base ligands and their respective gold(III) chelates. The gold(III) chelates 
have been designed to intercalate DNA and the next step is to determine the chemotherapeutic 
properties of the chelates. The chelates could interact with DNA in one of two ways: 
intercalation or groove binding. These binding modes have been explained in Chapters 1 and 5.  
DNA titrations and competitive DNA binding assays have been done on the synthesised 
complexes, but the results show limited intercalation. This is likely due to the bulky methyl 
groups found on the imidazole ring which cause steric hinderence when attempting to 
intercalate
between the aromatic DNA base pairs. The methyl groups cannot be removed entirely as their 
inductive effect is needed to stabilise the gold(III) ion. An alternative solution is to move the 




By using 1-(1H-imidazol-5-yl)ethanone instead of 4-methyl-1H-imidazole-5-carbaldehyde, it 
will create a larger planar aromatic region for intercalation while still retaining the inductive 
effect of the methyl groups needed to stabilse the gold(III) ion. This is an exciting new prospect 
which could maintain stability, while increasing the potential for DNA intercalation. 
Although the chelates were not shown to be intercalators the second binding option is groove 
binding. Molecules that bind in either the major or minor groove of DNA do not necessarily need 
to be planar. It is therefore possible that the current gold(III) chelates could act as groove 
binding agents and could still be therapeutics. This avenue needs to be further explored. To 
determine DNA groove binding, the method of choice employs emission spectroscopy. Nucleic 
acid dyes such as 40,6-diamidino-2-phenylindole (DAPI) are used to bind to DNA base pairs, 
which leads to an increase in fluorescence emissions. A second DNA groove binder (complex) is 
now introduced which ideally has a higher binding affinity than DAPI. The second groove binder 
displaces DAPI which leads to a decrease in emission. Since DAPI is a known groove binder, the 
decrease in emission would indicate that the complex has associated with the DNA via groove 
binding [1]. 
Another important objective for future work is tumour cell screening. This will determine the 
cytotoxicity of the chelates towards human tumor cell lines. Since there are many types of 
cancers, each chelate will likely have varying cytotoxicity towards each cell line. The variation of 
the bridging unit allows for the physico-chemical properties of the chelates to be tuned. This is 
an important aspect in the development of chemotherpeutics as it has been shown that small 
structural changes can have a marked effect on the lipophilicity of a compound. This can 
influence the efficiency with which a drug can cross the phospholipid bilayer of the cell wall and 
reach its cellular target. This will impact cytotoxicity. To this end, measuring the lipophilicity of 
the chelates by determining the octanol/water partition coefficient can give insight into 
potential cytotoxicity. It has also been shown that lipophilicity can influence DNA binding as the 
chelates must be stable in the hydrophobic core of the DNA helix [4], tuning this aspect could 
therefore improve the DNA binding affinity.  
One of the most important aspects in developing new chemotherapeutics is to increase the 
uptake of the compounds in neoplastic versus healthy tissue. This would likely reduce the side 
effects associated with current chemotherapies. This could be achieved by variations of the 
bridging unit to include biotin. Biotin is also known as vitamin H and is an important nutrient 
for living organisms due to its role as a cofactor for enzymes involved in carboxylation and 
decarboxylation [2]. There are many biotin receptors found in cancer tissues, therefore by 
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attaching biotin, the gold(III) chelate could show enhanced uptake in neoplastic tissue. The 























Figure 7.2.2: Proposed structure of the chelate with biotin attached. 
If the aspects proposed above for future research are successful then an important parameter to 
determine for any new drug is biodistribution. This is an experimental method of tracking the 
movements of a compound in an organism. One of the best methods for doing this is using a 
radioactive tracer. In this case 198Au will be synthesized and chelated to the most promising 
ligand. The chelate will then be administrated to rats. After selected periods of time the rats will 
be terminated using an isoflurane overdose. Vital organs, selected limbs and blood can then be 
counted for radiation to measure the uptake of the compound in specific organs. This method 
can also give an indication of the stability of the chelate in vivo as metal-based drugs are known 
to bind to serum proteins leading to large metal-serum protein adducts which are not easily 
excreted and may be toxic. The 198Au ion has several desirable characteristics which make it 
suitable for such biodistribution studies. The 198Au isotope with t½ = 2.7 days, Eβ = 0.97 MeV and 
Eγ = 411 keV was chosen for chelation by the Schiff base ligand as the high-energy γ photons are 
suitable for external detection by the single-photon imaging instrumentation used in nuclear 
medicine departments [3]. 
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